

Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline *ATM* sequence variants.

Marcy E. Richardson¹, Megan Holdren², Terra Brannan¹, Miguel de la Hoya³, Amanda B. Spurdle⁴, Sean V. Tavtigian⁵, Colin C. Young¹, Lauren Zec⁶, Susan Hiraki⁷, Michael J. Anderson⁸, Logan C. Walker⁹, Shannon McNulty¹⁰, Clare Turnbull¹¹, Marc Tischkowitz¹², Katherine Schon¹², Thomas Slavin¹³, William D. Foulkes¹⁴, Melissa Cline¹⁵, Alvaro N. Monteiro¹⁶, Tina Pesaran¹, Fergus J. Couch²

1. Ambry Genetics, Aliso Viejo, CA, USA
2. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
3. Molecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.
4. Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia
5. Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
6. Natera, Inc, San Carlos, CA, USA
7. GeneDx, Gaithersburg, MD, USA
8. Invitae Corporation, San Francisco, CA, USA
9. Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand
10. Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11. Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
12. Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
13. City of Hope Comprehensive Cancer Center, Duarte, CA, USA
14. Departments of Human Genetics, McGill University, Montreal, Quebec, Canada
15. UC Santa Cruz Genomics Institute, Mail Stop: Genomics, University of California, Santa Cruz, CA, USA
16. Department of Cancer Epidemiology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Abstract

The ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer (HBOP) Variant Curation Expert Panel (VCEP) is composed of internationally recognized experts in clinical genetics, molecular biology and variant interpretation. This VCEP made specifications for ACMG/AMP guidelines for the ataxia telangiectasia mutated (*ATM*) gene according to the Food and Drug Administration (FDA)-approved ClinGen protocol. These gene-specific rules for *ATM* were modified from the American College of Medical Genetics and Association for Molecular Pathology (ACMG/AMP) guidelines and were tested against 33 *ATM* variants of various types and classifications in a pilot curation phase. The pilot revealed a majority agreement between the HBOP VCEP classifications and the ClinVar-deposited classifications. Six pilot variants had conflicting interpretations in ClinVar and reevaluation with the VCEP's *ATM*-specific rules resulted in four that were classified as benign, one as likely pathogenic and one as a variant of uncertain significance (VUS) by the VCEP, improving the certainty of interpretations in the public domain. Overall, 28 the 33 pilot variants were not VUS leading to

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

an 85% classification rate. The ClinGen-approved, modified rules demonstrated value for improved interpretation of variants in *ATM*.

Introduction

The widespread adoption of low cost, high-throughput, next generation sequencing (NGS)-based multi-gene panel tests has led to a substantial increase in the detection of germline sequence variants. In 2015, in response to this increase, the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) provided a substantial update to their variant interpretation guidelines addressing many of the new challenges for variant interpretation^{1,2}. Because these guidelines are intended for use with any Mendelian disorder, gene- and disease-specific modifications may be needed to develop a tailored approach to variant classification. The process of tailoring variant interpretation guidelines is overseen by the National Institute of Health-funded Clinical Genome Resource (ClinGen) whose mission it is to develop an authoritative, comprehensive, central resource for expert-guided, gene- and variant-level information³⁻⁵. As part of this ClinGen initiative, the Hereditary Breast, Ovarian and Pancreatic Cancer (HBOP) Variant Curation Expert Panel (VCEP) formed in 2018, with a goal of specifying criteria of the 2015 ACMG/AMP baseline guidelines for clinical classification of variants in *ATM* (MIM 607585), *BARD1* (MIM 601593), *BRIP1* (MIM 605882), *CHEK2* (MIM 604373), *PALB2* (MIM 610355), *RAD51C* (MIM 602774), and *RAD51D* (MIM 602954) (<https://clinicalgenome.org/affiliation/50039/>). Based on the large number of variants and VUS in ClinVar, the Ataxia Telangiectasia mutated (*ATM*) tumor suppressor gene was selected for initial work of this VCEP.

ATM encodes a serine-threonine kinase involved in the cellular response to DNA damage⁶. Heterozygous loss-of-function (LoF) variants in *ATM* are associated with approximately 2-fold increased lifetime risks for breast cancer (MIM#114480) with a penetrance of 20-30%; and a 6.5-fold increased risk for pancreatic cancer⁷⁻¹¹. Biallelic pathogenic variants in *ATM* lead to the autosomal recessive disease Ataxia Telangiectasia (A-T) (MIM# 208900), a severe, early-onset disorder characterized by progressive cerebellar ataxia and ocular telangiectasias¹² and increased cancer risk most commonly for leukemia and lymphomas¹³. Large epidemiological and molecular studies have demonstrated that variants that cause A-T in the biallelic state are also expected to cause increased risk of breast and pancreatic cancer^{14,15}. As such, variants that cause A-T in the biallelic state are also considered by the HBOP VCEP to cause increased risk of breast and pancreatic cancer in the heterozygous state. Given the demonstrated increased risk for autosomal dominant and recessive disease, individuals with likely pathogenic/pathogenic (LP/P) variants in *ATM* may elect to increase cancer surveillance and/or be counseled for family planning. However, there are currently over 7,500 variants of uncertain significance (VUS) deposited to ClinVar, many of which are missense and non-coding variants (<https://www.ncbi.nlm.nih.gov/clinvar/?term=atm%5Bgene%5D&redir=gene> accessed 3/19/2024).

Therefore, the HBOP VCEP selected *ATM* for development of a validated set of variant classification rule specifications modeled on the baseline 2015 ACMG/AMP guidelines. The gene-specific rules for *ATM* along with application of these rules to curation of a series of *ATM* variants are described herein.

Methods

ClinGen HBOP VCEP

The HBOP VCEP formed in 2018 and is comprised of an international team of experts with relevant backgrounds in basic science research including protein functional analysis, clinical genetics, tumor pathology, computational principles, and/or variant interpretation. All members declared conflicts of interest as required by the FDA-approved ClinGen process, including several members who are full time employees at clinical diagnostic laboratories. The HBOP VCEP convened bi-weekly to consider the applicability, weight modifications, and gene-specific nuances of each of the categorical ACMG/AMP guidelines for *ATM*¹. Initial rules were drafted based on evidence in the literature, internal laboratory data, and expert

opinion and approved for pilot phase by ClinGen's Sequence Variant Interpretation (SVI) group, who oversees this process.

Pilot Phase

The *ATM*-specific rules were applied in a pilot test of 33 variants comprised of multiple different types (frameshift, nonsense, synonymous, intronic, canonical intronic, missense and structural variants), with different applicable evidence (high frequency variants, rare variants, variants identified in patients with A-T, variants in different functional domains, and variants tested in published functional assays), and/or selected for a variety of clinical assertions in ClinVar. Relevant clinical and allelic data from unpublished sources were solicited from the membership ahead of curation. Two curators independently evaluated variants and compared results. Differences were resolved first by discussion and agreement in a separate biocurator working group, that convened monthly. Differences were then escalated for a secondary review and consensus from the whole HBOP VCEP by vote. If needed, rules were modified or clarified in response to this process.

Final ATM Rules

Modifications made in response to the pilot study were submitted to the ClinGen SVI for review. The final round of modifications, as recommended by the SVI, were implemented, and resubmitted for approval. Final interpretations for each of the pilot variants were curated into the Variant Curation Interface (VCI) and ultimately deposited to ClinVar. Classifications followed the original five-tier model (Benign, Likely Benign, Variant of Uncertain Significance, Likely Pathogenic and Pathogenic) and evidence combinations with a few modifications that are supported by a Bayesian framework¹⁶. The most recent *ATM* guidelines can be found on the Criteria Specification Registry and will be updated periodically as the HBOP VCEP continues their work (<https://cspec.genome.network/cspec/ui/svi/doc/GN020>).

Results

Rules not adopted for *ATM* by the HBOP VCEP (PS2, PS4_Moderate, PM1, PM6, PP1, PP2, PP4, PP5, BS2, BS4, BP1, BP3, BP5, BP6)

The HBOP VCEP chose not to adopt numerous ACMG/AMP codes for *ATM* for several reasons (Table 1). First, breast cancer is relatively common and the majority of it is non-hereditary, or sporadic. Second, hereditary and sporadic breast cancer cannot be distinguished from each other at this time. And third, *ATM* has low penetrance for breast cancer, conveying only two-fold risk which leads to substantial phenocopy and unaffected carriers of pathogenic variants within a family. The codes that were not adopted are detailed below.

TABLE 1. SUMMARY OF ATM-SPECIFIC RULES SPECIFICATIONS		
Code	Original application	ATM-modified application
PVS1	Null variant in a gene where loss of function is a known mechanism of disease.	Per ATM Exon Map (Figure 1) and ATM PVS1 Decision Tree (Figure 2) <ul style="list-style-type: none"> •PVS1_Variant: Predicted splice defect •PVS1_Variant(RNA): Observed splice defect •NOTE: PVS1 and PVS1(RNA) has code combination restrictions: See Table 3
PS1	Same amino acid change as a previously established pathogenic variant regardless of nucleotide change	<ul style="list-style-type: none"> •Protein: This rule may be applied only when a splice defect is ruled out for both alterations either by RNA analysis and/or in silico splice predictions •RNA (use as PS1_Variant) per SVI guidelines: See PS1 table (Table 4)
PS2	De novo (paternity confirmed) in a patient with the disease and no family history.	Do not use for AD or AR disease
PS3	Well-established in vitro or in vivo functional studies supportive of a damaging effect	<ul style="list-style-type: none"> •Protein functional studies (Table 5) •PS3_Moderate: A-T (ATM null cell line) failure-to-rescue studies (typically target phosphorylation) PLUS confirmatory radiosensitivity assay; •PS3_Supporting: A-T (ATM null cell line) rescue study only; •No Weight: radiosensitivity only (non-specific) •RNA functional studies shall be coded as PVS1(RNA) (where RNA is for 'Observed')
PS4	The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls.	<ul style="list-style-type: none"> •Do not use for proband-counting studies •Case-control studies; p-value $\leq .05$ AND (Odds ratio, hazard ratio, or relative risk ≥ 2 OR lower 95% CI ≥ 1.5).
PM1	Located in a mutational hot spot and/or critical and well-established functional domain.	<ul style="list-style-type: none"> •Do not use: Benign and pathogenic variants are known to occur within the same domains and germline mutational hotspots are not well defined at this time
PM2	Absent/rare from controls in an ethnically-matched cohort population sample.	<ul style="list-style-type: none"> •Variant absent in gnomAD or present in $\leq .001\%$ in all sub-populations •EXCEPTION: under-represented sub-populations with N=1 but frequency $>.001\%$ •Not considered a conflicting piece of evidence for variants that otherwise are likely benign/benign •Use as PM2_Supporting (not moderate)
PM3	For recessive disorders, detected in trans with a pathogenic variant.	Per A-T PM3 tables (Table 6)
PM4	Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants.	<ul style="list-style-type: none"> •Do not use for in frame insertions and deletions as no data are available for this rule at this time •PM4 can be used for stop-loss variants.
PM5	Missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.	<ul style="list-style-type: none"> •Do not use for hotspot - Multiple amino acid substitutions at the same residue can be pathogenic or benign and bioinformatic tools cannot yet confidently distinguish them •Apply to frameshifting or truncating variants as PM5_supporting for variants with premature termination codons upstream of p.Arg3047 which are expected to be more severe than the most C-terminal pathogenic variant p.Arg3047*
PM6	Confirmed de novo without confirmation of paternity and maternity.	Do not use for AD or AR disease
PP1	Co-segregation with disease in multiple affected family members	<ul style="list-style-type: none"> •AD Condition: Co-segregation analysis in lower-penetrance genes can lead to false positive results •AR Condition: informative instances of co-segregation in A-T families are too rare to be formally analyzed at this time, however, this VCEP supports approaching this similarly to the ITGA2B/ITGB3 and Hearing Loss VCEPs who have outlined PP1 criteria for these autosomal recessive disorders
PP2	Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	Do not use: ATM does not have a specified low-rate of benign missense variation.
PP3	Multiple lines of computational evidence support a deleterious effect on the gene or gene product	<ul style="list-style-type: none"> •Protein Analysis: Metapredictor REVEL score $\geq .733s$ •RNA: SpliceAI score ≥ 2 •Do not use in conjunction with PVS1(RNA) •Use caution in applying the wrong type of computational evidence (protein vs. RNA) towards the cumulative body of evidence for the opposite mechanism.
PP4	Phenotype specific for disease with single genetic etiology.	<ul style="list-style-type: none"> •Do not use for AD disorder •For AR disorder, see PM3 for specific phenotype considerations (Table 6)
PP5	Reputable source recently reports variant as pathogenic but the evidence is not available to the laboratory to perform an independent evaluation	Do not use
BA1	Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes, or ExAC	$>0.5\%$ (.005)
BS1	Allele frequency is greater than expected for disorder	$>.05\%$ (.0005)
BS2	Observed in a healthy adult individual for a dominant (heterozygous) disorder with full penetrance expected at an early age.	Do not use: ATM has reduced penetrance
BS3	Well-established in vitro or in vivo functional studies shows no damaging effect on protein function	<ul style="list-style-type: none"> •Protein functional studies (BS3) •BS3_Moderate (Protein): Both radiosensitivity and ATM-null cell line rescue (usually phosphorylation of multiple substrates) are normal. Note 'Moderate' does not exist in the current ACMG weights for benign but can be considered as two supporting benign lines of evidence towards final classification •BS3_Supporting (Protein): Either radiosensitivity OR ATM-null cell line rescue (usually phosphorylation of multiple substrates) are normal NOTE: BP4 protein predictions may be used in conjunction with BS3 for protein effects •RNA: Do not use: See code BP7_Variant(RNA)
BS4	Lack of segregation in affected members of a family.	Do not use: ATM has reduced penetrance
BP1	Missense variant in gene where only LOF causes disease	Do not use: ATM has known missense pathogenic variation
BP2	Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder.	• See A-T PM3 BP2 table (Table 6)
BP3	In-frame deletions/insertions in a repetitive region without a known function	Do not use
BP4	Multiple lines of computational evidence suggest no impact on gene or gene product	<ul style="list-style-type: none"> •Protein Analysis: Metapredictor REVEL score $\leq .249$ •RNA: SpliceAI score ≤ 1
BP5	Variant found in a case with an alternate molecular basis for disease	Do not use
BP6	Reputable source recently reports variant as benign but the evidence is not available to the laboratory to perform an independent evaluation	Do not use
BP7	A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved.	<ul style="list-style-type: none"> BP7: Synonymous and deep intronic •Can be used for deep intronic variants beyond (but not including) +7 (donor) and -40 (acceptor) •May also apply BP4 to achieve Likely Benign •Is not considered a conflicting piece of evidence against a body of evidence supporting a pathogenic splice defect BP7_Variant(RNA): RNA functional studies •Lack of aberrant splice defect: Please see PVS1_Variant(RNA) section (above) for guidance on baseline weights and modifications of weight based on quality for RNA assays •NOTE: BP4 splice predictions may not be used in conjunction with BP7

PS2/PM6: De novo

The observation of a *de novo* variant in the setting of a new disease is evidence towards pathogenicity. The use of *de novo* instances is not informative for ATM because breast cancer as a 'new disease' cannot be confidently established given the commonness of sporadic breast cancer.

PS4_Moderate: Proband Counting

With rare variants where a case control analysis cannot be statistically powered, an approximation called 'proband counting' can be used instead. In this method, affected probands can be weighted/counted towards pathogenicity once they reach a certain number that is designed to accommodate the disease and penetrance. It is most useful for pathognomonic gene-disease relationships with high penetrance. Because many genes cause breast cancer predisposition, and because penetrance is low, proband counting does not apply to *ATM*.

PP1/BS4: Co-segregation

Segregation of a disease and a variant within the same family is evidence for pathogenicity. However, genes conferring lower risk (Relative Risk = 2) for autosomal dominant conditions, should not be considered for co-segregation analysis because an unrealistic number of pedigrees is needed to obtain a true positive result whilst avoiding a false positive result. For example, in a gene with a Relative Risk of 2, like *ATM*, the probability of obtaining a true positive result for PP1 (as supporting strength) caps at 80% with 40 pedigrees, however that same circumstance also comes with a ~3.5% chance of obtaining a false positive BP4 result¹⁷. Regarding the use of BS4 (lack-of-segregation) in families with biallelic A-T is theoretically feasible, however, siblings with the same two variants as the A-T affected proband would be captured under the BP2 code which is a biallelic-unaffected patient.

PP4/BS2: Phenotype

A patient who has a phenotype that is highly specific for a disease or an unaffected patient who has not manifested disease can be used in the pathogenic (PP4) or benign (BS2) direction, respectively. However, since hereditary and sporadic breast and pancreatic cancer cannot be distinguished and because the penetrance is low for breast cancer, neither situation can be satisfied for *ATM*.

BP5: Variant present in a patient with an alternate mechanism for disease

This rule does not apply, because there are numerous examples of patients carrying both an *ATM* LP/P variant in addition to a second LP/P in other genes whose phenotype is not different than if they were carriers of a single pathogenic variant¹⁸.

PM1: Variant in a functional domain without benign variation

Although *ATM* has well established functional domains, there are many benign variants described in these domains, based on allele frequency and homozygous occurrences alone (https://gnomad.broadinstitute.org/gene/ENSG00000149311?dataset=gnomad_r2_1 accessed 3/19/2024).

PP2 and BP1: Low Rate of Benign Missense Variation

Pathogenic missense variants in *ATM* have been described, and there is not a specified low rate of benign missense variation.

BP3: in-frame indels in a repetitive region

There are insufficient data to support the use of in-frame deletions/insertions in a repetitive region without a known function.

PP5 and BP6: Reputable Source

These rules regarding reputable sources have been discontinued at the recommendation of the SVI¹⁹

Population Based Rules (BA1, BS1 and PM2_Supporting)

BA1 and BS1. The HBOP VCEP compared parameters for both the autosomal dominant and autosomal recessive conditions ascribed to *ATM* to estimate population allele frequency thresholds using the Whiffen/Ware calculator²⁰; <https://cardiodb.org/allelefrequencyapp/>.

Because LP/P variants in *ATM* are considered a relatively infrequent cause of hereditary breast cancer the genetic heterogeneity was set to 0.02: in other words, as if 2% of hereditary breast cancer cases are caused by *ATM* LP/P variants. The allelic heterogeneity was conservatively set to 1.0: in other words, assuming that there is only one LP/P variant that causes *ATM*-related breast cancers. Lastly, the penetrance for *ATM* and breast cancer was conservatively set to 0.2 based on data from multiple studies of hereditary breast cancer^{10,11}. Using these parameters, and a prevalence of 1:8 women for breast cancer, the maximum credible allele frequency was 0.625%. Similarly, for A-T the autosomal recessive inheritance was selected along with a prevalence of 1:40,000^{21–25}. As *ATM* is the only gene that causes A-T, the genetic heterogeneity was set to 1.0 and penetrance was set to 0.90. Using these parameters, the maximum credible allele frequency is 0.527%. Given the conservative parameters put into the calculator and to simplify, the BA1 threshold was set to 0.5%. For BS1, all parameters remained the same except for the extremely conservative allelic heterogeneity value, which was dropped to 0.10, leading to an order-of-magnitude decrease in the maximum credible allele frequency of 0.05%. In applying these frequency codes, statistical models should be considered to account for error related to sample size such as the filtering allele frequency in gnomAD²⁶.

PM2. ClinGen has deviated from the Richards *et al* ACMG/AMP guidelines for PM2 and now recommends that this evidence code be uniformly down weighted to PM2_Supporting (https://www.clinicalgenome.org/site/assets/files/5182/pm2_-_svi_recommendation_-_approved_sept2020.pdf). This recommendation was adopted for rare *ATM* variants. Due to the incomplete penetrance, it is reasonable to expect that unaffected carriers are present in the general population. As such a variant does not need to be absent in the general population to apply PM2_Supporting. For *ATM*, rarity is considered as a general population frequency of $\leq 0.001\%$ in each subpopulation. Any alteration that exceeds 0.001% in a large general population database but for which there is only one carrier is still considered eligible for PM2_Supporting.

Loss-of-Function Codes (PVS1 and PVS1(RNA))

PVS1

LoF is the mechanism of disease for *ATM*^{22,27,28}. The rules governing the application and appropriate weight of PVS1 are based on the ClinGen SVI recommendations²⁹. There are five variant types that fall under the PVS1 category: nonsense and frameshift alterations; canonical (+/-1,2) splice site alterations (and some last-nucleotide alterations), gross deletions, gross duplications, and initiation codon alterations. Several features influence the weight ascribed to PVS1 including: 1) nonsense-mediated RNA decay (NMD); 2) the impact of an NMD-escaping effect on a critical functional domain 3) the size of the NMD-escaping effect relative to the size of the protein; and 4) gene-specific features.

***ATM* canonical transcript:** The reference transcripts considered by this VCEP are NM_000051.3/ENST00000278616.8. All exons from this transcript are considered constitutive exons without major alternative splice isoforms that could result in a rescue of PVS1-eligible variants^{30–33}. This transcript contains a non-coding first exon (Exon 1) and 62 subsequent coding exons: Exon 2-63 (Figure 1). Of note, *ATM* may be annotated with four non-coding first exons leading to legacy nomenclature references in historical data.

***ATM* Functional Domains:** *ATM* is comprised of two main functional domains: the N-Solenoid domain and the FATKIN domain. The N-terminal half of the protein is an α -solenoid structure (N-Solenoid) (amino acids 1-1892)³⁴ that is able to interact with nucleic acids and various protein partners. The Phosphoinositide 3-Kinase domain (PI3-K), the Focal Adhesion Targeting (FAT), and the Focal Adhesion Targeting Carboxyterminal (FATC)

collectively comprise the FATKIN domain of ATM (Figure 1). The FATKIN domain is directly responsible for ATM kinase function, which is essential for tumor suppressor activity. Therefore, the FATKIN domain is considered critical for protein function and NMD-escaping variants, including in-frame losses and truncations between p.Leu2980 and p.Arg3047, that adversely affect the FATKIN domain are given PVS1 as Very_Strong^{35–38}. The N-Solenoid domain is thought to be important for protein function because there are numerous patients affected with A-T who carry alterations that are known to lead to in-frame losses in the N-Solenoid domain (Supplementary Figure 1)^{30,32,39–49}. However, compared to the FATKIN domain, there are relatively few missense pathogenic mutations (<https://www.ncbi.nlm.nih.gov/clinvar/?term=atm%5Bgene%5D&redir=gene> accessed 3/19/2024). Because of this, in-frame single- or multi-exon losses impacting the N-Solenoid domain can receive PVS1_Strong.

ATM NM_000051.3/ENST00000278616.8




Figure 1. ATM Exon Numbering and Reading Frame. The ATM gene is depicted exon-by-exon. The amino acid size of each exon is depicted within the boxes in black text. The two major functional domains are outlined in red (N-Solenoid, comprised of sub-domains HEAT Repeat and TAN domain) and green outline (FATKIN domain comprised of the FAT and FAT-C sub-domains). Each exon is shaped to indicate the number of overhanging nucleotides at either end which will assist in determining any reading-frame changes from gross deletions or duplications of whole single- or multi-exons. A vertical line indicates a blunt start or end with no overhanging nucleotides. An upper overhang on either side represents a two-nucleotide overhang; A lower overhang represents a single-nucleotide overhang on that side. To use this diagram, a line drawn at the start and end of a deletion or duplication will be either parallel (in-frame event) or non-parallel (frameshift) as in the examples.

PVS1 Eligibility Boundaries: Because pathogenic variants in ATM cause both A-T in a biallelic state and cancer predisposition in a heterozygous state, this VCEP was able to leverage evidence from A-T cohorts to inform PVS1 boundaries. At the N-terminus, it was determined that variants destroying the initiation codon are ascribed PVS1 as Very_Strong due to the identification of numerous A-T affected individuals harboring p.Met1? variants^{45,47,50–53}. In addition, LoF alterations lying between p.Met1? and the next downstream, in-frame methionine at p.Met94 have also been observed in A-T patients supporting that downstream methionine residues are unable to serve as an alternate start codon that would produce a rescue effect^{54–56}. At the C-terminus, p.Arg3047 is considered the last critical amino acid based on many reports of a nonsense variant at this position in patients with A-T^{30,43,45,47,57–62}. Therefore, LoF alterations impacting codons between p.Met1 and p.Arg3047 are eligible for PVS1 at varying weights according to the PVS1 Decision Tree (Figure 2).

1. PVS1 decision tree, based on ACMG/AMP rationale (Tayoun et al, 2018), introducing some code strength modifications (upgrades and downgrades as indicated), and a few instances not addressed by Tayoun et al. Specifically: (i) GT-AG variants not affecting coding exons, (ii) +2T>C variants predicted to create de novo functional GC sites, (iii) +2C>T variants targeting native GC sites and, (iv) considering the relevance of the protein domain targeted by ≥1 exon duplications in deciding the PVS1 evidence strength

2. We have considered NM_000051 the clinically relevant reference transcript (63 exons, 62 coding exons, start codon located in exon 2, coding a 3056aa protein)

<p>3. We are not aware of any potential rescue transcripts (i.e. for the sake of simplicity, in the decision tree we will not refer to "exon is absent from biologically-relevant transcripts")</p> <p>4. We define two clinically relevant domains: (i) an N-Solenoid (containing TAN and HEAT repeat domains) spanning residues 1-1892 (coded by total exons 2 to 38), and (ii) a C-terminal FATKIN domain spanning residues 1893-3056 (coded by total exons 38 to 63).</p> <p>5. Based on clinical and structural data, we have considered in-frame alterations targeting HEAT repeats as PVS1_Strong, the only exception being any very small in-frame alterations with PROVEAN score suggesting pathogenic, that were considered PVS1_Supporting</p> <p>6. Based on clinical and structural data, we have considered in-frame alterations targeting FATKIN as PVS1, the only exception being very small in-frame alterations with PROVEAN score suggesting pathogenic, that were considered PVS1_Supporting</p> <p>7. As far as we know, p.Arg3047Ter is the last PTC variant known to be pathogenic</p> <p>8. The existence of experimental data (literature and/or personal communication from HBOP VCEP members) supporting the PVS1 weight are denoted by <u>red-underline</u> in the PVS1 decision tree.</p>			
Initiation Codon	≥1 pathogenic variant(s) upstream of closest potential in-frame start codon (p.Met94)	PVS1 (upgraded from PVS1_Moderate)	
Nonsense or Frameshift	Predicted to undergo NMD (p.Ser2_Glu2979)	PVS1	
	Not predicted to undergo NMD (p.Leu2980_Val3056)	Truncated/alterd region is critical to protein function FATKIN (2980-3047) critical p.(Arg3047Ter) in exon 63 the most C-terminal variant known to be pathogenic FATKIN (3048-3056) Role of region in protein function is unknown	
Deletion (Single exon to full gene)	Full gene deletion	PVS1_SA	
	Single to multi exon deletion – Disrupts reading frame and is predicted to undergo NMD	PVS1	
	Single to multi exon deletion – Disrupts reading frame and is NOT predicted to undergo NMD	Truncated/alterd region is critical to protein function (deletion involving ≥ 1 exon in the FATKIN domain) (exons 38 to 63)	PVS1 (upgraded from PVS1_Strong)
	Single to multi exon deletion Preserves reading frame	Altered region relevant for protein function (deletion involving ≥ 1 exon in the HEAT repeats) (exons 2 to 38) Altered region relevant for protein function (deletion involving ≥ 1 exon in the HEAT repeats) (exons 2 to 38)	PVS1_Strong PVS1 (upgraded from PVS1_Strong)
Duplication (≥1 exon in size and must be completely contained within gene)	Reading frame disrupted and NMD predicted to occur	PVS1 (if proven in tandem) -or- PVS1_Strong (if presumed in tandem)	
	Preserves reading frame, but disrupts the FATKIN domain (both breakpoints contained within the domain)	PVS1 (if proven in tandem) -or- PVS1_Strong (if presumed in tandem)	
	Preserves reading frame, but disrupts the HEAT repeats domain (both breakpoints contained within the domain)	PVS1_Strong (if proven in tandem) -or- PVS1_Moderate (if presumed in tandem)	
	Preserves reading frame and contains the full coding sequence of one HEAT repeats and one FATKIN domain	PVS1_N/A	
	Proven not in tandem	PVS1_N/A	
GT—AG 1,2 splice Sites G>non-G at last nucleotide of exon when adjacent intronic sequence is not gtrgt (where r is a purine) can provide same weight as PVS1 indicates but notched one-level-down in strength	Exon skipping or use of a cryptic splice site does not affect the coding sequence	PVS1_N/A c.-31+1G> A, T, C c.-31+2T> C, G, A c.-30-2A> G, C, T c.-31-1G> A, C, T	
	N-Solenoid (HEAT repeats) (p.Met1_Glu1892) (exons 2 to 38)	Exon skipping/ cryptic site disrupts reading frame (all predicted to undergo NMD)	
	FATKIN (p.Ser1893-Val3056) (exons 38 to 63) p.(Arg3047Ter) in exon 63 the most C-terminal variant known to be pathogenic	Exon skipping or use of a cryptic splice site preserves reading frame	PVS1_Strong (variants listed in B)
		Special case: use of a cryptic splice site preserving reading frame + very small Indel alteration + in silico supporting pathogenic (PROVEAN)	PVS1_Supporting (variants listed in C) (downgraded from PVS1_Strong)
		Exon skipping/cryptic site disrupts reading frame Predicted to undergo NMD (p.Ser1893_Glu2979)	PVS1 (variants listed in D)
		Exon skipping or cryptic splice site disrupts reading frame Not predicted to undergo NMD (p.Leu2980_Val3056)	PVS1 (variants listed in E) (upgraded from PVS1_Strong)
		Exon skipping or use of a cryptic splice site preserving reading frame	PVS1_Supporting (variants listed in F) (downgraded from PVS1_Strong)
Special case: use of a cryptic splice site preserving reading frame + very small Indel alteration + in silico supporting pathogenic (PROVEAN)	PVS1_Supporting (variants listed in F) (downgraded from PVS1_Strong)		
GC—AG 1,2 splice Sites	Variant improves the donor site	PVS1_N/A c.7515+2C> T	

N-terminal HEAT repeats (exon 2 to exon 38)		C-terminal FATKIN (exon 38 to exon 63) p.(Arg3047Ter) in exon 63 the most C-terminal variant known to be pathogenic			
Exon skipping or use of a cryptic splice site disrupts reading frame (all predicted to undergo NMD)					
PVS1 (list A)	PVS1 (list A)	PVS1 (list A)	PVS1 (list D)	PVS1 (list D)	
c.72+1G> A, C, T	c.2467-2A> G	c.4110-2A> C, G, T	c.5674+2T> A, C, G	c.8010+1G> A, C, T	
c.72+2T> A, C, G	c.2467-1G> A	c.4110-1G> A, C, T	c.5675-2A> G	c.8010+2T> A, C, G	
c.73-2A> C, G, T	c.2638+1G> A, C, T	c.4236+1G> A, C, T	c.5675-1G> A, C, T	c.8011-2A> C, G, T	
c.73-1G> A, C, T	c.2638+2T> A, C, G	c.4236+2T> A, C, G	c.5762+1G> A, C, T	c.8011-1G> A, C, T	
c.185+1G> A, C, T	c.2639-2A> C, G, T	c.4237-1G> A	c.5763-2A> C, G, T	c.8152-2A> G	
c.185+2T> A, C, G	c.2639-1G> A, C, T	c.4436+1G> A, C, T	c.5763-1G> A, C, T	c.8152-1G> A	
c.186-2A> C, G, T	c.2838+1G> A, C, T	c.4436+2T> A, C, G	c.6006+1G> A, C, T	c.8419-2A> G	

c.186-1G>	A, C, T	c.2838+2T>	A, C, G	c.4437-1G>	A	c.6006+2T>	A, C, G	c.8419-1G>	A
c.331+1G>	A, C, T	c.2921+1G>	A, C, T	c.4611+1G>	A, C, T	c.6007-2A>	C, G, T	c.8584+1G>	A, C, T
c.331+2T>	A, C, G	c.2921+2T>	A, C, G	c.4611+2T>	A, C, G	c.6007-1G>	A, C, T	c.8584+2T>	A, C, G
c.497-2A>	C, G, T	c.2922-2A>	C, G, T	c.4777-2A>	C, G, T	c.6095+1G>	A, C, T	c.8672-2A>	C, G, T
c.497-1G>	A, C, T	c.2922-1G>	A, C, T	c.4777-1G>	A, C, T	c.6095+2T>	A, C, G	c.8672-1G>	A, C, T
c.662+1G>	A, C, T	c.3077+1G>	A, C, T	c.4909+1G>	A, C, T	c.6096-2A>	C, G, T	c.8786+1G>	A, C, T
c.662+2T>	A, C, G	c.3077+2T>	A, C, G	c.4909+2T>	A, C, G	c.6096-1G>	A, C, T	c.8786+2T>	A, G
c.663-2A>	C, G, T	c.3078-2A>	C, G, T	c.5006-2A>	C, G, T	c.6198+1G>	A, C, T	c.8787-2A>	C, G, T
c.663-1G>	A, C, T	c.3078-1G>	A, C, T	c.5006-1G>	A, C, T	c.6198+2T>	A, C, G	c.8787-1G>	A, C, T
c.901+1G>	A, C, T	c.3153+1G>	A, C, T	c.5177+1G>	A, C, T	c.6199-1G>	A	c.8850+1G>	A, C, T
c.901+2T>	A, C, G	c.3153+2T>	A, C, G	c.5177+2T>	A, C, G	c.6347+1G>	A, C, T	c.8850+2T>	A, C, G
c.902-2A>	C, G, T	c.3154-2A>	C, G, T	c.5178-2A>	C, G, T	c.6347+2T>	A, G	c.8851-1G>	A
c.902-1G>	A, C, T	c.3154-1G>	A, C, T	c.5178-1G>	A, C, T	c.6453-2A>	C, G, T		
c.1065+1G>	A, C, T	c.3284+1G>	A, C, T	c.5319+1G>	A, C, T	c.6453-1G>	A, C, T		
c.1065+2T>	A, C, G	c.3284+2T>	A, C, G	c.5319+2T>	A, C, G	c.6573-2A>	C, G, T		
c.1066-2A>	C, G, T	c.3285-2A>	C, G, T	c.5320-2A>	C, G, T	c.6573-1G>	A, C, T		
c.1066-1G>	A, C, T	c.3285-1G>	A, C, T	c.5320-1G>	A, C, T	c.6807+1G>	A, C, T		
c.1235+1G>	A, C, T	c.3402+1G>	A, C, T	c.5496+2T>	A, C, G	c.6807+2T>	A, G		
c.1235+2T>	A, C, G	c.3402+2T>	A, C, G	c.5497-2A>	C, G, T	c.7090-2A>	C, G, T		
c.1236-2A>	C, G, T	c.3403-2A>	C, G, T	c.5497-1G>	A, C, T	c.7090-1G>	A, C, T		
c.1236-1G>	A, C, T	c.3403-1G>	A, C, T	c.5674+1G>	A, C, T	c.7307+1G>	A, C, T		
c.1803-2A>	C, G, T	c.3577-2A>	C, G, T	c.5674+2T>	A, C, G	c.7307+2T>	A, C, G		
c.1803-1G>	A, C, T	c.3577-1G>	A, C, T	c.5675-2A>	G	c.7308-2A>	C, G, T		
c.1899-2A>	C, G, T	c.3746+1G>	A, C, T	c.5675-1G>	A, C, T	c.7308-1G>	A, C, T		
c.1899-1G>	A, C, T	c.3746+2T>	A, C, G	c.5762+1G>	A, C, T	c.7515+1G>	A, C, T		
c.2124+1G>	A, C, T	c.3747-2A>	C, G, T	c.5762+2T>	A, C, G	c.7515+2C>	A, G		
c.2124+2T>	A, C, G	c.3747-1G>	A, C, T			c.7516-2A>	C, G, T		
c.2125-2A>	C, G, T	c.3994-2A>	C, G, T			c.7516-1G>	A, C, T		
c.2125-1G>	A, C, T	c.3994-1G>	A, C, T			c.7789-2A>	C, G, T		
c.2251-2A>	C, G, T	c.4109+1G>	A, C, T			c.7789-1G>	A, C, T		
c.2251-1G>	A, C, T	c.4109+2T>	A, C, G			c.7927+1G>	A, C, T		
						c.7927+2T>	A, C, G		

N-terminal HEAT repeats (exons 2 to 38)
Exon skipping or use of a cryptic splice site preserves reading frame

PVS1 Strong (list B)	
c.332-2A>	C, G, T
c.332-1G>	A, C, T
c.496+1G>	A, C, T
c.496+2T>	A, C, G
c.1607+1G>	A, C, T
c.1607+2T>	A, C, G
c.1608-2A>	C, G, T
c.1608-1G>	A, C, T
c.1802+1G>	A, C, T
c.1802+2T>	A, C, G
c.1898+1G>	A, C, T
c.1898+2T>	A, C, G
c.2250+1G>	A, C, T
c.2250+2T>	A, C, G
c.2376+1G>	A, C, T
c.2376+2T>	A, C, G
c.2377-2A>	C, G, T
c.2377-1G>	A, C, T
c.2466+1G>	A, C, T
c.2466+2T>	A, C, G
c.3576+1G>	A, C, T
c.3576+2T>	A, C, G
c.3993-1G>	A, C, T
c.3993+2T>	A, C, G
c.4612-2A>	C, G, T
c.4612-1G>	A, C, T
c.4776+1G>	A, C, T
c.4776+2T>	A, C, G

PVS1 Strong (list B)	
c.4910-2A>	C, G, T
c.4910-1G>	A, C, T
c.5005+1G>	A, C, T
c.5005+2T>	A, C, G
c.5496+1G>	A, C, T

Very small Indel predicted damaging by PROVEAN		
PVS1 Supporting (list C)		PROVEAN'
c.2467-2A>	C, T	
c.2467-1G>	C, T	-8.91
c.2839-2A>	C, G, T	
c.2839-1G>	A, C, T	-17.71
c.4237-2A>	C, G, T	
c.4237-1G>	C, T	-19
c.4437-2A>	C, G, T	
c.4437-1G>	C, T	-20.08
c.5675-2A	C, T	-4.98

C-terminal FATKIN (exon 38 to 63)
Exon skipping or use of a cryptic splice site preserves reading frame, or PTC not predicted to undergo NMD

PVS1 (list E)	
c.5918+1G>	A, C, T
c.5918+2T>	A, C, G
c.5919-2A>	C, G, T
c.5919-1G>	A, C, T
c.6348-2A>	C, G, T
c.6348-1G>	A, C, T
c.6452+1G>	A, C, T
c.6452+2T>	A, C, G
c.6572+1G>	A, C, T
c.6572+2T>	A, C, G
c.6808-2A>	C, G, T
c.6808-1G>	A, C, T
c.6975+1G>	A, C, T
c.6975+2T>	A, C, G
c.6976-2A>	C, G, T
c.6976-1G>	A, C, T
c.7089+1G>	A, C, T
c.7089+2T>	A, C, G
c.7629+1G>	A, C, T
c.7629+2T>	A, G
c.7630-2A>	C, G, T
c.7630-1G>	A, C, T
c.7788+1G>	A, C, T
c.7788+2T>	A, C, G
c.8151+1G>	A, C, T
c.8151+2T>	A, C, G

PVS1 (list E)	
c.8268+1G>	A, C, T
c.8268+2T>	A, C, G
c.8269-1G>	A
c.8418+1G>	A, C, T
c.8418+2T>	A, C, G
c.8585-2A>	C, G, T
c.8585-1G>	A, C, T
c.8671+1G>	A, C, T
c.8671+2T>	A, C, G
c.8851-2A>	C, G, T
c.8851-1G>	C, T
c.8987+1G>	A, C, T
c.8987+2T>	A, G
c.8988-2A>	C, G, T
c.8988-1G>	A, C, T

Very small Indel predicted damaging by PROVEAN		
PVS1 Supporting (list F)		PROVEAN
c.6199-2A>	C, G, T	
c.6199-1G>	C, T	-14.76
c.7928-2A>	C, G, T	
c.7928-1G>	A, C, T	-6.13
c.8152-2A>	C, T	
c.8152-1G>	C, T	-73.69
c.8269-2A>	C, G, T	
c.8269-1G>	C, T	-34.54
c.8419-2A>	C, T	
c.8419-1G>	C, T	-6.32

1. Choi, Y., and Chan, A.P. (2015). PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics* 31, 2745. [10.1093/BIOINFORMATICS/BTV195](https://doi.org/10.1093/BIOINFORMATICS/BTV195).

Figure 2. PVS1 Decision Tree for ATM. PVS1 eligible variant types are split into five categories: initiation codon variants, nonsense and frameshift variants, ≥ 1 exon deletions, ≥ 1 exon duplications and last NT/canonical splice variants. Considerations related to NMD, N and C terminal boundaries, domain involvement, tandemness, and splice prediction/observation inform the weight that can be afforded to the PVS1 criterion. Small in-frame events were predicted with PROVEAN and scores are provided. Nucleotides in red-underline have splice effects reported in the literature.

Gross deletions: Single-to-multi-exon deletions that are frameshifting and NMD-prone receive PVS1 weight at Very_Strong as per the original 2018 PVS1 guidelines²⁹. Alterations producing NMD-escaping transcripts that adversely affect the N-Solenoid receive PVS1_Strong and those adversely affecting the FATKIN domain receive PVS1 as Very_Strong. The HBOP VCEP has made a diagram to assist with discerning the reading frame disruption of gross deletions and duplications (Figure 1).

Gross duplications: Single-to-multi-exon duplications that do not involve either the 5' or 3' untranslated regions (UTRs) are eligible for PVS1 weight whether they are confirmed or presumed in tandem. PVS1 (as Very_Strong) and PVS1_Strong can be applied for in-frame events confirmed or presumed to disrupt the FATKIN domain, respectively; and PVS1_Strong and PVS1_Moderate can be applied for in-frame events confirmed or presumed to disrupt the N-Solenoid domain, respectively. Care should be taken to ensure that the functional domains are *disrupted* by the duplication which means both the 5' and 3' breakpoint of the duplication must be within the same domain. Duplications that have one breakpoint in the N-solenoid domain and one breakpoint in the FATKIN domain do not disrupt either domain and do not receive any PVS1 weight.

Splice variants: Canonical splice variants are defined as the +/- 1 and 2 positions in the introns surrounding an exon as well as some alterations at the last nucleotide of the exon. If the sequence does not conform to the consensus U2 donor site of Ggtrrgt (where the capital G is the last-nucleotide position of the exon and where r is any purine) then the impact of a last nucleotide substitution on splicing is expected to be greater. Such alterations are eligible for PVS1 weight but are reduced by one strength level from the corresponding +1,2 baseline weight provided in the PVS1 Decision Tree (Figure 2). Each possible +/-1,2 splice variant is parsed into a PVS1 list (A to F) depending on reading frame and impact on the N-Solenoid or FATKIN domains (Figure 2). Figure 2 was informed by *in silico* score from SpliceAI and/or PROVEAN, in conjunction with published and unpublished splicing data. Of note, there are several variants that receive PVS1_Supporting because they are predicted to make use of an in-frame alternate splice site that preserves the reading frame and leads to a small insertion or deletion that is predicted by PROVEAN to be deleterious (Figure 2, Lists C and F). There are also several candidate variants that do not receive any PVS1 weight because they are +2T>C alterations that do not have a predicted splice impact by SpliceAI. Although rare, +2T>C alterations are known to produce predominantly wildtype transcripts⁶³. There is also one splice site at *ATM* c.7515+2 that is atypical in that it has a native cytosine instead of the consensus thymine. Therefore, a C>T substitution here is predicted to improve the native splice sequence and it receives no PVS1 weight.

PVS1(RNA): Any spliceogenic variant, whether canonical, exonic, or deeper intronic, that is confirmed by RNA studies to have a deleterious splice defect can be coded as PVS1(RNA). The application of PVS1(RNA) supplants any other predictive lines of evidence (PVS1 or PP3). Of note, PS3, the code for functional data supporting a pathogenic event, is not used for RNA data because it is reserved for downstream (e.g. protein) functional effects which can be observed in conjunction with an RNA defect and applied in addition to PVS1(RNA).

The weight for PVS1(RNA) can be variably ascribed based on curator judgement of the quality and quantitative result of the RNA assay according to recent recommendations by the SVI⁶⁴. In contrast, RNA functional studies establishing a lack of aberrant splicing can be coded as BP7(RNA). The weight for BP7(RNA) can be variably ascribed from Supporting to Strong based on curator judgment of the quality of the RNA assay.

Computational/predictive data-driven rules (PS1, PM4, PM5, PP3, BP4, BP7)

PS1. A variant that produces the same protein change as a known pathogenic alteration can be given PS1 towards pathogenicity. This rule may only be applied when a splice defect is ruled out for both the known LP/P alteration and the variant under evaluation by *in silico* splice predictions or RNA evidence. If splicing is a factor for both variants, PS1 can be used as an RNA hotspot and the weight applied is per the ClinGen SVI recommendations (Table 2)⁶⁴.

TABLE 2. PS1 CODE WEIGHTS FOR VARIANTS WITH SAME PREDICTED SPLICING EVENT AS KNOWN (LIKELY) PATHOGENIC VARIANT

Variant under assessment (VUA)	Baseline computational/predictive code applicable to VUA	Position of comparison variant relative to VUA	PS1 code applicable to VUA	
			with P comparison variant	with LP comparison variant
Located outside splice donor/acceptor ±1,2 dinucleotide positions	PP3	same nucleotide	PS1	PS1_Moderate
	PP3	within same splice donor/acceptor motif (including at±1,2 positions)	PS1_Moderate	PS1_Supporting
Located at splice donor/acceptor ±1,2 dinucleotide positions	PVS1	within same splice donor/acceptor ±1,2 dinucleotide	PS1_Supporting	N/A
	PVS1	within same splice donor/acceptor region, but outside ±1,2 dinucleotide ^a	PS1_Supporting	PS1_Supporting
	PVS1_Strong, PVS1_Moderate, or PVS1_Supporting	within same splice donor/acceptor ±1,2 dinucleotide	PS1	N/A
	PVS1_Strong, PVS1_Moderate, or PVS1_Supporting	within same splice donor/acceptor region, but outside ±1,2 dinucleotide ^a	PS1_Moderate	PS1_Supporting

Prerequisite for all: the predicted event of the VUA must precisely match the predicted event of the comparison (likely) pathogenic variant (e.g., both predicted to lead to exon skipping, or both to lead to enhanced use of a cryptic splice motif, AND the strength of the prediction for the VUA must be of similar or higher strength than the strength of the prediction for the comparison [likely] pathogenic variant). For an exonic variant, predicted or proven functional effect of missense substitution(s) encoded by the VUA and (likely) pathogenic variant should also be considered before application of this code. Dinucleotide positions refer to donor and acceptor dinucleotides in reference transcript(s) used for curation. Designated donor and acceptor motif ranges should be based on position weight matrices for intron category (see methods). For GT-AG introns these are defined as follows: the donor motif, last 3 bases of the exon and 6 nucleotides of intronic sequence adjacent to the exon; acceptor motif, first base of the exon and 20 nucleotides upstream from the exon boundary. Consider other motif ranges for non-GT-AG introns.

^a If relevant, splicing assay data for a pathogenic variant outside a ±1,2 dinucleotide position may be used to update a PVS1 decision tree and hence the applicable PVS1 code for a ±1,2 dinucleotide variant.

PM4. In frame deletions and insertions as well as variants disrupting the native stop codon may be eligible for PM4. However, for *ATM*, there are no data available at this time to inform the use of in-frame insertions or deletions. Stop-loss variants in *ATM* are eligible for PM4 due to the identification of numerous A-T patients harboring such pathogenic alterations^{45,56}.

PM5. This rule is ascribed to missense variants at an amino acid residue where another pathogenic missense alteration has been identified. However, amino acid substitutions at a single residue in *ATM* can be pathogenic or benign. Thus, the use of this rule is not recommended. However, this rule has been co-opted as PM5_Supporting to increase the evidence for pathogenicity for LoF alterations being ascribed PVS1 or PVS1(RNA) as

Very_Strong. This rule is governed by *ATM*'s lack of alternative splicing events that would produce a functional protein leading to a putative rescue of LoF alterations by splicing the variant out. In this manner, the use of PVS1 and PM5_Supporting will classify all *ATM* LoF variants as likely pathogenic even if they do not meet PM2_Supporting. PVS1/PVS1(RNA)-eligible variants (applied as Very_Strong) that do meet rarity (PM2_Supporting) will be classified as likely pathogenic with the addition of PM5_Supporting.

PP3/BP4 Protein. This VCEP favors the use of the metapredictor REVEL for single nucleotide variation and Provean for small in-frame indels as a single predictor to anticipate the impact of a protein change⁶⁵⁻⁶⁷. A REVEL score ≥ 0.733 is considered damaging (PP3). And a score ≤ 0.249 is considered neutral. This threshold is based on the general recommendation and not derived as an *ATM*-specific threshold at this time⁶⁵. This was further supported by application to prediction of damaging effect in large functional datasets for multiple cancer genes⁶⁸.

PP3/BP4 RNA. The VCEP uses SpliceAI as a sole predictor due to its ability to accurately predict loss of native splice sites and creation of cryptic sites⁶⁹. This VCEP did not declare gene-specific thresholds for SpliceAI but recommends those set forth by the SVI in applying PP3 to non-canonical splice variants with a SpliceAI score of ≥ 0.2 and BP4 to variants with a SpliceAI score ≤ 0.1 ⁶⁴. In the event that RNA data are available and they reflect a substantial variant-specific impact, do not use both PVS1(RNA) and PP3 or BP4. However, in the event that RNA data are available and they reflect no variant-specific impacts, PP3 or BP4 may be applied in conjunction with BP7(RNA) (See Table 3). BP4 may also be used in conjunction with BP7 (see below)⁶⁴.

BP7. This rule was originally intended for synonymous variants, however, the VCEP applied the rule to deep-intronic variants beyond (but not including) +7 at the donor site and -40 at the acceptor site. Per the SVI's recent guidance, this code is to be applied only when BP4 is met, in which case both BP4 and BP7 would be applied⁶⁴ (See Table 3). Using these modifications, many synonymous and deep intronic variants can be classified towards benign by applying both BP7 and BP4, in the absence of conflicting data.

TABLE 3. RESTRICTIONS ON COMBINING CRITERIA								
	PP3	PS3 BS3	PS1	PVS1	PVS1 (RNA)	BP4	BP7	BP7 (RNA)
PP3		✓	✓	X	X	N/A	N/A	✓
PS3 BS3	✓		N/A	✓	✓	✓	✓	✓
PS1	✓	N/A		N/A	N/A	N/A	N/A	N/A
PVS1	X	✓	N/A		X	X	X	X
PVS1(RNA)	X	✓	N/A	X		X	X	X
BP4	N/A	✓	N/A	X	X		✓	✓
BP7	X	✓	N/A	X	X	✓		X
BP7(RNA)	✓	N/A	N/A	X	X	✓	X	

N/A: Not applicable because the codes are unrelated

Functional evidence (PS3/BS3)

PS3/BS3. This is applied to protein functional studies or studies that are downstream of RNA effects. For *ATM*, there are multiple well-established functional studies that employ the use of *ATM*-null cell lines to observe the general rescue of radiosensitivity and/or *ATM*-specific events such as phosphorylation of *ATM* substrates (Table 4)^{46,70,71}. Because many of the published assays have only a few variants, they contain insufficient known-pathogenic and known-benign controls for Bayesian validation⁷². However, because variant controls in several studies behave as expected in these assays the VCEP has approved a maximum weight of PS3_Moderate and BS3_Moderate for a combination of functional studies that are concordant for a non-functional or functional result, respectively. For non-functional results to

be used as PS3_Moderate, both an ATM-specific functional result and a non-specific radiosensitivity functional result should agree. If there is disagreement between results then no weight should be applied towards PS3. If only the ATM-specific-study (e.g. ATM auto- or trans-phosphorylation at specific residues) result is available and reflects non-functional, a maximum weight of PS3_Supporting can be given. However, because a non-functional result from a radiosensitivity assay is not specific to an ATM defect, a non-functional result in a radiosensitivity assay alone does not achieve any PS3 weight. In the benign direction, a neutral result in either an ATM-specific assay or a radiosensitivity assay can be ascribed BS3_Supporting per each. Of note, both PP3/BP4 *in silico* protein predictions and PS3/BP4 protein functional studies can be co-applied.

Note: RNA functional studies reflecting aberrant splicing should be coded as PVS1(RNA) and lack of aberrant splicing as BP7(RNA). Because PS3/BS3 eligible observations measure effects downstream of splicing, it may be appropriate to apply these codes in conjunction with PVS1(RNA)/BP7(RNA).

TABLE 4. ATM FUNCTIONAL STUDIES

ATM kinase activity			
PMID	18634022	19431188	11805335
DOI / link	10.1002/humu.20805	DOI: 10.1002/humu.21034	10.1073/pnas.012329699
Author	Mitui	Barone	Scott
Year	2009	2009	2002
Assay (general description)	Stable transfection of ATM-based cDNA constructs in an ATM null cell line; ATM kinase activity assayed by Western Blotting of ATM substrates.	Stable transfection of ATM-based cDNA constructs in an ATM null cell line; ATM kinase activity assayed by Western Blotting of ATM substrates.	Stable transfection of ATM-based cDNA constructs in an ATM null cell line; ATM kinase activity assayed by Western Blotting of ATM substrates.
Material used (patient cells, engineered variants, cell lines, animal model, etc.)	ATM null patient LCL cells (AT7LA1-homozygous for a truncating mutation-c.1563_1564delAG); variants introduced by site-directed mutagenesis.	ATM null patient LCLs (patient 118-3 with two truncating mutations, c.796_797insGATT and c.2921+1G>A); variants introduced by site-directed mutagenesis.	ATM null patient LCLs (AT1ABR); variants introduced by site-directed mutagenesis.
Readout type (qualitative/quantitative)	qualitative- bands on a gel	quantitative- Western blot images scanned using a densitometer	qualitative-band on a gel
Readout description	phosphorylation status of ATM-S1981 and SMC1 (at S957 or S966) tested by Western Blot 1 hr after cells were irradiated with 2 or 10 Gy. Cells were treated with CdCl ₂ to induce ATM expression from a metallothionein promoter II.	Phosphorylation status of SMC1 (Ser-966); NBS1 (Ser-343); CHK2 (Thr-68); p53 (Ser-15); ATM serine 1981 tested by Western Blot at multiple timepoints after cells were irradiated with 5 gray (0, 30 mins, 60 mins) or mock irradiated. Cells were treated with zinc chloride to induce ATM expression from a metallothionein promoter II.	Cells were treated with 6 Gy of ionizing radiation and kinase assays were performed 1 hr after radiation. Phosphorylation status of p53-Ser-15 was assayed directly on cell lysates ("in vivo") or by immunoprecipitation of flag-tagged ATM from cell extracts followed by phosphorylation of a p53 substrate (p531-40, "in vitro"). Cells were treated with CdCl ₂ 6 h before irradiation to induce ATM expression from a metallothionein promoter II.
Biological replicates (met/not met)	uncertain/not described	not met	not met
Technical replicates (met/not met); description	uncertain/not described	Y; 3; not sure if biological or technical	uncertain/not described
Basic positive control (met/not met); description	met; WT cDNA (pMAT1) and ATM WT LCLs (NAT2)	met; WT cDNA (pTAM2)	met; WT cDNA (pMAT3)
Basic negative control (met/not met); description	met; ATM null cells (AT7LA1)	met; empty cDNA (pMEP4)	met; un-induced cells

Validation controls P/LP (#)	0; c.5908C>T (p.Q1970*) - unclear if tested in this assay/data not shown	0	5 AT mutants "c.7636del9,p.SRI2564del3; c.8147T>C, p.V2716A; c.8546G>C p.R2849P; c.8599G>C p.G2867R; c.7987delGTT p.V2662del"
Validation controls B/LB (#)	0; c.1744T>C(p.F582L) and c.2119T>C (p.S707P)- unclear if tested in this assay/data not shown	0	0
Statistical analysis (general description)	uncertain/not described	uncertain/not specified	uncertain/not described
Threshold for normal readout	authors label a normal readout as "normal" in table 1. "normal" is based on the output of the WT construct (pMAT1)	WT level of kinase activity (group 1) (relative to WT pTAM2)	not provided, but curator can distinguish as present or absent
Threshold for abnormal readout	authors label an abnormal read out as ND (non-detectable); TD, (trace detected) in table 1.	no detectable kinase activity (group 2) or reduced level of kinase activity (group 3), (relative to WT pTAM2). Authors note that ATM Serine 1981 phosphorylation may not be a good indicator of overall ATM kinase activity.	not provided, but curator can distinguish as present or absent
Approved assay (y/n)	Y	Y	Y
Proposed strength	PS3_supporting BS3_Supporting	PS3_Supporting; BS3_supporting	PS3_Supporting BS3_supporting

ATM radiosensitivity			
PMID	18634022	11805335	11805335
DOI / link	10.1002/humu.20805	10.1073/pnas.012329699	10.1073/pnas.012329699
Author	Mitui	Scott	Scott
Year	2009	2002	2002
Assay (general description)	Stable expression of cDNA constructs in an ATM null cell line; cellular radiosensitivity was assayed as a read-out for ATM function.	Stable transfection of ATM-based cDNA constructs in an ATM null cell line; cellular radiosensitivity was assayed as a read-out for ATM function.	Stable transfection of ATM-based cDNA constructs in an ATM null cell line; cellular radiosensitivity was assayed as a read-out for ATM function.
Material used (patient cells, engineered variants, cell lines, animal model, etc.)	ATM null patient LCL cells (AT7LA1-homozygous for a truncating mutation- c.1563_1564delAG); variants introduced by site-directed mutagenesis.	ATM null patient LCLs (AT1ABR); variants introduced by site-directed mutagenesis.	ATM null patient LCLs (AT1ABR); variants introduced by site-directed mutagenesis.
Readout type (qualitative/quantitative)	quantitative	quantitative	quantitative
Readout description	% survival fraction (SF) (determined by MTT staining of viable cell colonies after irradiation with 1 gy). Cells were treated with CdCl2 to induce ATM expression from a metallothionine promoter II.	Cells were treated with 1 Gy of y-rays and fifty metaphases were analyzed for each sample, and radiation induced chromosome aberrations (ICAs) were determined. Cells were treated with CdCl2 6 h before irradiation to induce ATM expression from a metallothionine promoter II	Cells were treated with 1-4 Gy of y-rays and the number of viable cells was determined daily up to 4 days post irradiation. Cells were treated with CdCl2 6 h before irradiation to induce ATM expression from a metallothionine promoter II.
Biological replicates (met/not met)	uncertain/not specified	uncertain/not specified	
Technical replicates (met/not met); description	uncertain/not specified	uncertain/not specified	3; unclear if biological or technical

Basic positive control (met/not met); description	met; WT cDNA (pMAT1) and ATM WT LCLs (NAT9)	met; WT cDNA and WT ATM cells (C3ABR)	met; WT cDNA and WT ATM cells (C3ABR)
Basic negative control (met/not met); description	met; ATM null cells (AT7LA1)	met; ATM null cells (AT1ABR)	met; ATM null cells (AT1ABR)
Validation controls P/LP (#)	0; c.5908C>T (p.Q1970*) (not clear if tested in this assay/data not shown)	5 AT mutants "c.7636del9,p.SRI2564del3; c.8147T>C, p.V2716A; c.8546G>C p.R2849P; c.8599G>C p.G2867R; c.7987delGTT p.V2662del"	5 AT mutants "c.7636del9,p.SRI2564del3; c.8147T>C, p.V2716A; c.8546G>C p.R2849P; c.8599G>C p.G2867R; c.7987delGTT p.V2662del"
Validation controls B/LB (#)	0; c.1744T>C(p.F582L) and c.2119T>C (p.S707P') (not clear if tested in this assay/data not shown)	0	0
Statistical analysis (general description)	uncertain/not specified	uncertain/not specified	uncertain/not specified
Threshold for normal readout	SF >36% (50.1±13.5%) is considered as radio-normal (Sun et al., 2002).	authors state ~ 1 ICA (<1.5 would work)	not specified, propose % survival <10 at 4 days
Threshold for abnormal readout	A SF of <21% (13.1±7.2%) has been determined to be the radiosensitive range (Sun et al., 2002).	2.98–3.20 ICAs per metaphase	not specified, propose % survival >10 at 4 days
Approved assay (y/n)	Y		
Proposed strength	PS3_moderate (can only be applied if PS3_supporting from kinase assay is met)/ BS3_Supporting (can be added with BS3_supporting from kinase assay) No weight should be applied if only radiosensitivity is available No weight should be applied if radiosensitivity and kinase assay are conflicting	PS3_moderate (can only be applied if PS3_supporting from kinase assay is met)/ BS3_Supporting (can be added with BS3_supporting from kinase assay) No weight should be applied if only radiosensitivity is available No weight should be applied if radiosensitivity and kinase assay are conflicting	PS3_moderate (can only be applied if PS3_supporting from kinase assay is met)/ BS3_Supporting (can be added with BS3_supporting from kinase assay) No weight should be applied if only radiosensitivity is available No weight should be applied if radiosensitivity and kinase assay are conflicting

Phenotype-related rules (PS4, PM3 and BP2)

PS4. Case-control studies with *ATM* pathogenic variants are expected to yield odds ratio (OR) >2 based on the known increased lifetime breast cancer risks for pathogenic variant carriers^{10,11}. ORs should be statistically significant with a p-value <0.05 and a lower 95% confidence interval >1.5.

PM3. Biallelic pathogenic variants in *ATM* cause A-T. Laboratory studies are available to help rule out differential diagnoses of other ataxia-associated diseases. Of note, A-T can manifest in an atypical fashion, often called variant A-T, that usually presents in childhood with similar features but has a slower progression. The VCEP has created criteria for patients to meet a 'confident' or 'consistent' *ATM*-associated A-T phenotype with additional weight afforded to those with a 'confident' phenotype. There are several considerations in addition to phenotype that need to be reviewed when weighting and applying PM3, including identification of a second *ATM* variant, phase of the second variant, or zygosity, and general population frequency of the variant under consideration. For the application of PM3, points ascribed to multiple probands are additive and the cumulative points can be used as in Table 5 to assign a final weight.

BP2. Each adult (over 18 years of age) without features of A-T that has an *ATM* variant under consideration in the homozygous state, *in trans*, or phase unknown with a LP/P *ATM* variant contributes to BP2 evidence. There are two important considerations in the application of BP2: 1) The source of the data, where a laboratory setting gets stronger weight than a database setting, due increased rigor in the former and risk of a false positive

result due to technical issues like allele drop-out in the latter; and 2) Homozygous individuals have a maximum total weight of -2 points (equivalent to BP2_Moderate) no matter how many independent instances there are. This protects against the assumption that a variant is benign when in reality it might be hypomorphic and pathogenic, but an individual may have sub-clinical or very mild features that may be overlooked by a cancer ascertainment bias. The risk of such a phenomenon is reduced in a compound heterozygous state where the other allele is more likely to have typical risks and stronger presentation. One example of very mild homozygous A-T patients (who are affected with dystonia and not cancer) is caused by the founder alteration *ATM* c.6200C>A (p.Ala2067Asp)⁷³. Excepting homozygous cases, multiple cases of biallelic adult patients unaffected by A-T are additive and can be ascribed BP2 weight based on the cumulative points defined in Table 5 up to a maximum weight of BP2_Strong.

TABLE 5. PM3 AND BP2 BIALLELIC CODE STRENGTHS				
PM3				
Classification/Zygoty of other variant ¹	Points per unrelated A-T Proband (PM3)			
	Confirmed in <i>trans</i>	Phase unknown	Second variant unidentified or VUS	Homozygous
Phenotype <i>confident</i>	4	2	1	2
Phenotype <i>consistent</i>	2	1	0.5	1
BP2				
	Points per Unaffected Adult (>18yo) Proband (BP2)			Homozygous (max -2.0)
	Confirmed in <i>trans</i>	Phase Unknown		
Pathogenic or Likely pathogenic variant in a patient	-4	-2		<u>Laboratory Setting</u> -2 <u>Database Setting</u> -1
¹ May not exceed general population frequency > .01%				
Do not use observations in cis				

Points				
Supporting	Moderate	Strong	Very Strong	
PM3				
1	2	4	8	
BP2				
-1	-2	≤-4.0	N/A	

Phenotype Details

- **CONFIDENT PHENOTYPE** (must include Laboratory result)
 - Presence of ≥2 Laboratory results 1-4 (see notes) -OR-
 - Presence of Clinical feature 1a or 1b **AND** presence of Laboratory result 1 or 2 -OR-
 - Presence of Clinical feature 2 or 3 **AND** Laboratory result 1 or 2
- **CONSISTENT PHENOTYPE** (does not require laboratory result)
 - Presence of two or more Clinical features of ataxia (1a-1e) -OR-
 - Presence of one Clinical feature 1a or 1b **AND** either Clinical feature 2 or 3

Clinical features (Neurological and MRI findings):

- Progressive cerebellar ataxia, manifesting as:
 - Progressive truncal/limb ataxia
 - Cerebellar degeneration (atrophy of the frontal and posterior vermis and both hemispheres by MRI).
 - Oculomotor apraxia (inability to follow an object across visual fields) or abnormal ocular saccades (rapid refixation from one object to another).
 - Choreoathetosis or dystonia (involuntary movements; twisting and repetitive movements, abnormal postures).
 - Peripheral axonal neuropathy OR Anterior horn cell neuronopathy
- Oculocutaneous telangiectasia of the conjunctivae, ears, or face.
- Immunodeficiency (often frequent infections) and/or leukemia/lymphoma.

Laboratory Results:

- ATM protein levels ≤ 15% of controls in patient fibroblast or lymphoblastoid cell lines. If ATM protein levels are slightly greater than 15%, the ATM kinase activity must be shown to be "negative or low or residual" (see notes).
- Elevated serum alpha-fetoprotein (AFP) levels >65ug/L in a patient ≥ 2 years old.
- Increased sensitivity to ionizing radiation in patient fibroblast or lymphoblastoid cell lines.

4. Presence of a 7;14 chromosomal translocation in patient peripheral blood cells ($\geq 5\%$ of cells).

Notes:

1. ATM protein levels $\leq 15\%$ of control levels show $>95\%$ sensitivity and $>98\%$ specificity for diagnosing (A-T). Protein levels $>15\%$ may arise due to a missense variant, a leaky splicing variant, a variant resulting in a kinase-dead protein (where protein levels may not be affected), or a diagnosis other than A-T.
2. When assigning case report criteria based solely on laboratory results (i.e., presence of TWO or more of laboratory results 1-4), there is a greater likelihood that the most specific laboratory results #1 and #2 will be available, and that there will be some clinical indication that the individual(s) has A-T.
3. When assessing homozygous or *in trans* variants (with a likely pathogenic or pathogenic ATM variant) for possible downgrade in an unaffected individual, the individual should be 18 years or older with no evidence of A-T.

Modified Evidence Code Combinations

The HBOP VCEP adopted the original ACMG-AMP categorical evidence code combinations¹ with two modifications. To achieve a minimum likely pathogenic classification for PVS1-eligible alterations, the combination of PVS1 plus one additional supporting line of pathogenic evidence is allowed to achieve likely pathogenic. In addition, one strong line of evidence in the benign direction is sufficient to achieve a likely benign classification. Both specific modifications are in line with a Bayesian model of variant interpretation published by the SVI¹⁶ (Table 6). The use of several code combinations is explicitly permitted or restricted by this VCEP and/or the SVI and these are listed in Table 3.

TABLE 6. RULES FOR COMBINING CRITERIA	
PATHOGENIC CRITERIA	
Pathogenic	<ol style="list-style-type: none"> 1. 1 Very Strong (PVS1, PVS1(RNA) PM3_VeryStrong) AND <ol style="list-style-type: none"> ≥ 1 Strong (PS1-PS4, PM3_Strong, PP1_Strong) OR ≥ 2 Moderate (PM1-PM6, PP4_Moderate, PP1_Moderate) OR 1 Moderate (PM1-PM6, PP4_Moderate, PP1_Moderate) and 1 Supporting (PP1-PP5, PM3_Supporting) OR ≥ 2 Supporting (PP1-PP5, PM3_Supporting) 2. ≥ 2 Strong (PS1-PS4, PM3_Strong, PP1_Strong) OR 3. 1 Strong (PS1-PS4, PM3_Strong, PP1_Strong) AND <ol style="list-style-type: none"> ≥ 3 Moderate (PM1-PM6, PP4_Moderate, PP1_Moderate) OR 2 Moderate (PM1-PM6, PP4_Moderate, PP1_Moderate) AND ≥ 2 Supporting (PP1-PP5, PM3_Supporting) OR 1 Moderate (PM1-PM6, PP4_Moderate, PP1_Moderate) AND ≥ 4 Supporting (PP1-PP5, PM3_Supporting) 4. 1 Moderate (PM1-PM6, PP4_Moderate, PP1_Moderate) AND ≥ 4 Supporting (PP1-PP5, PM3_Supporting)
Likely Pathogenic	<ol style="list-style-type: none"> 1. 1 Very Strong (PM3_VeryStrong) AND 1 Moderate (PP1-PP5, PM3_Supporting) OR 1 Very Strong (PVS1, PM3_VeryStrong) AND 1 Supporting (PP1-PP5, PM3_Supporting) OR 1 Strong (PS1-PS4, PM3_Strong, PP1_Strong) AND 1-2 Moderate (PM1-PM6, PP4_Moderate, PP1_Moderate) OR 1 Strong (PS1-PS4, PM3_Strong, PP1_Strong) AND ≥ 2 Supporting (PP1-PP5, PM3_Supporting) OR ≥ 3 Moderate (PM1-PM6, PP4_Moderate, PP1_Moderate) OR 2 Moderate (PM1-PM6, PP4_Moderate, PP1_Moderate) AND ≥ 2 Supporting (PP1-PP5, PM3_Supporting) OR 1 Moderate (PM1-PM6, PP4_Moderate, PP1_Moderate) AND ≥ 4 Supporting (PP1-PP5, PM3_Supporting)
BENIGN CRITERIA	
Benign	<ol style="list-style-type: none"> 1. 1 Stand-Alone (BA1) OR 2. ≥ 2 Strong (BS1-BS4)
Likely Benign	<ol style="list-style-type: none"> 1. 1 Strong OR 1 Strong (BS1-BS4) and 1 Supporting (BP1-BP7, BS3_Supporting, BP7_Supporting(RNA)) OR ≥ 2 Supporting (BP1-BP7, BS3_Supporting, BP7_Supporting(RNA))

Pilot

Biocurators evaluated 33 variants of varying type and ClinVar classification in a pilot study. Clinical data were collected regarding co-occurrence data from participating clinical diagnostic laboratories and disseminated in a deidentified fashion to the biocurators. Each variant was reviewed independently by two biocurators who applied lines of evidence for a final classification. Evidence codes and classifications were compared among the biocurator group and reviewed by the HBOP VCEP. Evidence codes and classifications approved by the VCEP were submitted for SVI approval and ultimately deposited to ClinVar. The pilot curation set consisted of 10 non-splicing PVS1-eligible alterations (of a variety of variant types); 13 missense alterations (including one generated by an indel); 7 intronic variants;

and 3 synonymous variants. Of these 9 had a consensus B/LB classification in ClinVar, 13 had a consensus P/LP classification in ClinVar; 6 had conflicting interpretations, and 5 were considered a VUS. After developing and applying the VCEP rules, the final classifications achieved were 9 benign variants, 2 likely benign variants, 4 likely pathogenic variants, 12 pathogenic variants, and 6 variants of uncertain significance (Figure 3, Table 7).

Among the variants considered (likely) benign in ClinVar (n=9), the VCEP classified six as (likely) benign and three as VUS (*ATM* c.5556_5557delinsGA (p.Asp1853Asn), *ATM* c.7919C>G (p.Thr2640Ser) and *ATM* c.331+7G>A). Among the variants that were (likely) pathogenic in ClinVar (n=13), the VCEP classified all 13 as (likely) pathogenic. Among 11 variants classified as VUS or conflicting in ClinVar, the VCEP classified five as (likely) benign (four due to application of BA1 or BS1, and one due to the combination of BP4 and BP7), three as (likely) pathogenic (two with PM3_Strong or PM3_Very Strong; and one with the application of PVS1), and three as VUS due to limited evidence (Figure 3, Table 7). The final classifications asserted by the VCEP were submitted to the ClinGen VCI and deposited in ClinVar.

TABLE 7. PILOT VARIANTS RESULTS							
Variant Type	Variant Information	ClinVar ID	Allele Registry ID	ClinVar Classification	ClinVar Star	HBOP Final Classification	HBOP Curation Criteria Applied
frameshift indel	NM_000051.4(ATM):c.1122_1123del (p.Glu376IlefsTer2)	818362	n/a	P/LP	2 star	Pathogenic	PM2_supporting, PVS1, PM3, PM5_supporting
frameshift indel	NM_000051.4(ATM):c.3245_3247delinsTGAT (p.His1082LeufsTer14)	3033	CA298025	P/LP	2 star	Pathogenic	PVS1, PM2_supporting, PM3_very-strong, PM5_supporting
frameshift indel	NM_000051.4(ATM):c.6997dup	140818	CA345709	P/LP	2 star	Pathogenic	PM2_supporting, PVS1, PM3_strong, PM5_supporting
gross del	NC_000011.10:g.(?_108287594)_(-108287721_?)del	453341	n/a	P	1 star	Pathogenic	PVS1, PM2_Supporting, PM5_Supporting
gross dup	NC_000011.9:g.(?_108137888)_(-10825611_?)dup	583716	n/a	P	1 star	Likely pathogenic	PVS1_Strong, PM3, PM2_Supporting
in frame indel	NM_000051.4(ATM):c.8578_8580delTCT(p.Ser286Odel)	3018	CA198490	VUS	2 star	Pathogenic	PM3_very-strong, PM2_supporting, PP3
in frame indel	NM_000051.4(ATM):c.1905_1910del (p.His635_His636del)	141289	CA165011	VUS	2 star	Uncertain significance	PM2_supporting, PP3
missense	NM_000051.4(ATM):c.2614C>T (p.Pro872Ser)	133610	CA157083	B/LB	2 star	Benign	BA1, BP2_strong, BP4
missense	NM_000051.4(ATM):c.3118A>G (p.Met104OVal)	3027	CA151920	B/LB	2 star	Benign	BA1, BP2_strong, BP4
missense	NM_000051.4(ATM):c.6995T>C (p.Leu2332Pro)	133631	CA157165	B/LB	2 star	Benign	BA1, BP4, BP2_strong
missense	NM_000051.4(ATM):c.146C>G (p.Ser49Cys)	3048	CA202190	B/LB	1 star	Benign	BA1, BP2_strong
missense (indel)	NM_000051.4(ATM):c.5556_5557delinsGA (p.Asp1853Asn)	929198	n/a	B/LB	2 star	Uncertain significance	PM2_supporting, PP3
missense	NM_000051.4(ATM):c.1073A>G (p.Asn358Ser)	127329	CA286708	Conflicting B/LB/VUS	1 star	Benign	BS1, BP2_strong, BP4
missense	NM_000051.4(ATM):c.3925G>A (p.Ala1309Thr)	127377	CA242620	Conflicting B/LB/VUS	1 star	Benign	BS1, BP2_strong, BP4
missense	NM_000051.4(ATM):c.3284G>A (p.Arg1095Lys)	141522	CA165678	Conflicting LP/VUS	1 star	Uncertain significance	PM2_supporting, PVS1_strong
missense	NM_000051.4(ATM):c.7919C>G (p.Thr2640Ser)	231842	CA10579274	LB	1 star	Uncertain significance	PM2_supporting
missense	NM_000051.3(ATM):c.8546G>C (p.Arg2849Pro)	490737	CA382518439	LP	2 star	Likely pathogenic	PS3_moderate, PM2_supporting, PP3, PM3
missense	NM_000051.4(ATM):c.7271T>G (p.Val2424Gly)	3023	CA115930	P/LP	2 star	Pathogenic	PS3_moderate, PS4, PM3_very-strong, PP3, PP1
missense	NM_000051.4(ATM):c.3137T>C (p.Leu1046Pro)	186558	CA195169	VUS	2 star	Likely pathogenic	PM2_supporting, PP3, PM3_strong, PP4
missense	NM_000051.3(ATM):c.8734A>G (p.Arg2912Gly)	133641	CA157198	VUS	2 star	Uncertain significance	PP3, BP2_strong
nonsense (C-term)	NM_000051.4(ATM):c.9139C>T (p.Arg3047Ter)	3029	CA115937	P	2 star	Pathogenic	PS3_supporting, PM3_very-strong, PVS1
nonsense (mid)	NM_000051.4(ATM):c.1442T>G (p.Leu481Ter)	453367	CA382534080	P/LP	2 star	Pathogenic	PM2_supporting, PM3_strong, PVS1, PM5_supporting
splice	NM_000051.4(ATM):c.2639-17G>T	140763	CA163513	B	2 star	Benign	BA1, BP4, BP2_strong

splice	NM_000051.4(ATM):c.1066-6T>G	3038	CA151456	Conflicting B/LB/VUS	1 star	Benign	BS1, BP2_strong
splice	NM_000051.4(ATM):c.8268+1G>A	420799	CA1661925 2	Conflicting LP/VUS	1 star	Likely pathogenic	PVS1, PM2_supporting
splice	NM_000051.4(ATM):c.332-1G>A	231535	CA6264590	LP	2 star	Pathogenic	PM3_strong, PM2_supporting, PVS1_strong
splice	NM_000051.4(ATM):c.1607+1G>T	220555	CA348209	P/LP	2 star	Pathogenic	PM3_very-strong, PVS1_strong, PM2_supporting
splice	NM_000051.4(ATM):c.8585-2A>C	407718	CA1661345 4	P/LP	2 star	Pathogenic	PVS1, PM2_supporting, PM3_strong
splice	NM_000051.4(ATM):c.331+7G>A	453461	CA6586561 49	LB	2 star	Uncertain significance	BP4
start loss	NM_000051.4(ATM):c.2T>C (p.Met1?)	187275	CA197209	P/LP	2 star	Pathogenic	PVS1, PM2_supporting, PM3_very-strong, PP4
synonymous	NM_000051.4(ATM):c.1176C>G (p.Gly392=)	142140	CA167509	B	2 star	Benign	BP2_strong, BA1, BP4, BP7
synonymous	NM_000051.4(ATM):c.5544T>C (p.Asp1848=)	184944	CA190548	LB	2 star	Likely benign	BP4, BP7
synonymous	NM_000051.4(ATM):c.8751C>T (p.Gly2917=)	453745	CA6266433	VUS	2 star	Likely benign	BP4, BP7, PM2_supporting




Figure 3. ATM Pilot Variant Categorization. 33 pilot variants are displayed as community classification in ClinVar (left) where VUS/LP/P conflicting interpretation variants and VUS/LB/B conflicting interpretation variants are binned along with consensus VUS as “ClinVar VUS/Conflict”. Interpretation with the HBOP Rules specifications for ATM are on the right. Granular detail of the type of conflict and the type of variant are presented in the table. PTC: Premature Termination Codon; CV: ClinVar

Discussion

The routine employment of Next-Generation Sequencing represents major advancement in the detection of pathogenic variants in hereditary cancer genes. However, a concomitant

and seemingly exponential increase in the detection of variants of uncertain significance is an unfortunate discomfort for many patients and care providers. While it is not possible to resolve the classification of all variants, the development of a set of rules to harmonize classifications across diagnostic and research laboratories can decrease uncertainty related to differential classifications within the public domain. The HBOP VCEP was tasked to define such ACMG/AMP guidelines for *ATM* under the FDA-approved ClinGen VCEP process. This body of work describes the decisions made by the VCEP towards that goal with the ultimate benefit of improving patient outcomes.

The Spanish *ATM* Working Group (Sp*ATM*-WG) defined gene-specific ACMG/AMP style rules for *ATM*, with many similar decisions on rules specifications (Supplementary Table 1)⁷⁴. However, this VCEP also has substantial departures from the Sp*ATM*-WG rules that result largely from a more in-depth analysis related to the FDA-approved process that requires ClinGen SVI and HC-CDWG oversight and collaboration related to rules development. For example, this VCEP has justified the up-weighting of the PM3 and BP2 biallelic codes while the Sp*ATM*-WG adopted the original SVI-expounded recommendations (https://clinicalgenome.org/site/assets/files/3717/svi_proposal_for_pm3_criterion_-_version_1.pdf). Another difference is the Sp*ATM*-WG assignment of PS3 to variants identified in A-T patients who do not have sufficient *ATM* expression or substrate phosphorylation. The HBOP VCEP considers this a phenotypic line of evidence rather than a functional line of evidence as this result is not necessarily variant-specific, rather a molecular confirmation of the disease-state of the patient. This concept is incorporated into the VCEP interpretation for PM3. Lastly, among other differences, the HBOP VCEP has elected to omit certain codes for A-T patients that Sp*ATM*-WG does apply including *de novo* codes PM6 and PS2, co-segregation codes BS4 and PP1, and PS4 proband counting, which this VCEP applies as PM3.

The careful in-depth consideration of each rule has had an impact on ClinVar classified variants leading to a substantial decrease in the conflicting/VUS rate by nearly 50% (ClinVar n=11; VCEP n=6). The improvement of this VUS rate is likely related to three major features: 1) data sharing of otherwise siloed clinical data among participating clinical diagnostic laboratories towards the application of PM3 and BP2 biallelic codes; 2) the establishment of BA1 and BS1 frequency thresholds leading to the increased number of LB/B variants; and 3) the justified increase in weight applied to A-T patients under PM3 leading to the increased number of LP/P variants. The VCEP is performing ongoing curation and further rule modifications taking into consideration any new information that may be forthcoming, including the development of any new *ATM* functional studies. Using this method, this VCEP aims to further reduce VUS rates and discordance in variant interpretations submitted to ClinVar with the ultimate goal of improving risk assessment and family genetic counseling.

1. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 17, 405–424. 10.1038/GIM.2015.30.
2. Plon, S.E., Eccles, D.M., Easton, D., Foulkes, W.D., Genuardi, M., Greenblatt, M.S., Hogervorst, F.B.L., Hoogerbrugge, N., Spurdle, A.B., and Tavtigian, S. V. (2008). Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. *Hum Mutat* 29, 1282–1291. 10.1002/HUMU.20880.
3. Nussbaum, R.L., Rehm, H.L., and ClinGen (2015). ClinGen and Genetic Testing. *N Engl J Med* 373, 1377–1378. 10.1056/NEJMc1508700.

4. Rehm, H.L., Berg, J.S., Brooks, L.D., Bustamante, C.D., Evans, J.P., Landrum, M.J., Ledbetter, D.H., Maglott, D.R., Martin, C.L., Nussbaum, R.L., et al. (2015). ClinGen--the Clinical Genome Resource. *N Engl J Med* 372, 2235–2242. 10.1056/NEJMSR1406261.
5. Karam, R., Pesaran, T., and Chao, E. (2015). ClinGen and Genetic Testing. *N Engl J Med* 373, 1376–1377. 10.1056/NEJMc1508700.
6. Cremona, C.A., and Behrens, A. (2014). ATM signalling and cancer. *Oncogene* 33, 3351–3360. 10.1038/ONC.2013.275.
7. Marabelli, M., Cheng, S.C., and Parmigiani, G. (2016). Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk. *Genet Epidemiol* 40, 425–431. 10.1002/GEPI.21971.
8. Fan, X., Wynn, J., Shang, N., Liu, C., Fedotov, A., Hallquist, M.L.G., Buchanan, A.H., Williams, M.S., Smith, M.E., Hoell, C., et al. (2021). Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network. *JNCI Cancer Spectr* 5. 10.1093/JNCICS/PKAB044.
9. Hsu, F.C., Roberts, N.J., Childs, E., Porter, N., Rabe, K.G., Borgida, A., Ukaegbu, C., Goggins, M.G., Hruban, R.H., Zogopoulos, G., et al. (2021). Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. *JAMA Oncol* 7, 1664–1668. 10.1001/JAMAONCOL.2021.3701.
10. Dorling, L., Carvalho, S., Allen, J., González-Neira, A., Luccarini, C., Wahlström, C., Pooley, K.A., Parsons, M.T., Fortuno, C., Wang, Q., et al. (2021). Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *N Engl J Med* 384, 428–439. 10.1056/NEJMOA1913948.
11. Hu, C., Hart, S.N., Gnaolivu, R., Huang, H., Lee, K.Y., Na, J., Gao, C., Lilyquist, J., Yadav, S., Boddicker, N.J., et al. (2021). A Population-Based Study of Genes Previously Implicated in Breast Cancer. *N Engl J Med* 384, 440–451. 10.1056/NEJMOA2005936.
12. Veenhuis, S., van Os, N., Weemaes, C., Kamsteeg, E.-J., Willemsen, M., Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., et al. (2023). Ataxia-Telangiectasia. *GeneReviews*.
13. Olsen, J.H., Hahnemann, J.M., Børresen-Dale, A.L., Brøndum-Nielsen, K., Hammarstrom, L., Kleinerman, R., Kääriäinen, H., Lönnqvist, T., Sankila, R., Seersholm, N., et al. (2001). Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. *J Natl Cancer Inst* 93, 121–127. 10.1093/JNCI/93.2.121.
14. Ahmed, M., and Rahman, N. (2006). ATM and breast cancer susceptibility. *Oncogene* 25, 5906–5911. 10.1038/SJ.ONC.1209873.
15. Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., Byrd, P., Taylor, M., and Easton, D.F. (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. *J Natl Cancer Inst* 97, 813–822. 10.1093/JNCI/DJI141.
16. Tavtigian, S. V., Greenblatt, M.S., Harrison, S.M., Nussbaum, R.L., Prabhu, S.A., Boucher, K.M., and Biesecker, L.G. (2018). Modeling the ACMG/AMP Variant Classification Guidelines as a Bayesian Classification Framework. *Genet Med* 20, 1054. 10.1038/GIM.2017.210.

17. Belman, S., Parsons, M.T., Spurdle, A.B., Goldgar, D.E., and Feng, B.J. (2020). Considerations in assessing germline variant pathogenicity using cosegregation analysis. *Genet Med* 22, 2052–2059. 10.1038/S41436-020-0920-4.
18. Agaoglu, N.B., Bychkovsky, B.L., Horton, C., Lo, M.-T., Polfus, L., Carraway, C., Hemyari, P., Young, C., Richardson, M.E., Scheib, R., et al. (2024). Cancer burden in individuals with single versus double pathogenic variants in cancer susceptibility genes. *Genetics in Medicine Open* 2, 101829. 10.1016/J.GIMO.2024.101829.
19. Biesecker, L.G., and Harrison, S.M. (2018). The ACMG/AMP reputable source criteria for the interpretation of sequence variants. *Genet Med* 20, 1687–1688. 10.1038/GIM.2018.42.
20. Whiffin, N., Minikel, E., Walsh, R., O'Donnell-Luria, A.H., Karczewski, K., Ing, A.Y., Barton, P.J.R., Funke, B., Cook, S.A., Macarthur, D., et al. (2017). Using high-resolution variant frequencies to empower clinical genome interpretation. *Genet Med* 19, 1151–1158. 10.1038/GIM.2017.26.
21. Swift, M., Morrell, D., Massey, R.B., and Chase, C.L. (1991). Incidence of cancer in 161 families affected by ataxia-telangiectasia. *N Engl J Med* 325, 1831–1836. 10.1056/NEJM199112263252602.
22. Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, and Bishop DT (1986). The incidence and gene frequency of ataxia-telangiectasia in the United States. *Am J Hum Genet* 39, 573–583.
23. Zortea, M., Armani, M., Pastorello, E., Nunez, G.F., Lombardi, S., Tonello, S., Rigoni, M.T., Zuliani, L., Mostacciuolo, M.L., Gellera, C., et al. (2004). Prevalence of inherited ataxias in the province of Padua, Italy. *Neuroepidemiology* 23, 275–280. 10.1159/000080092.
24. Anheim, M., Fleury, M., Monga, B., Laugel, V., Chaigne, D., Rodier, G., Ginglinger, E., Boulay, C., Courtois, S., Drouot, N., et al. (2010). Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. *Neurogenetics* 11, 1–12. 10.1007/S10048-009-0196-Y.
25. Anheim, M., Fleury, M., Monga, B., Laugel, V., Chaigne, D., Rodier, G., Ginglinger, E., Boulay, C., Courtois, S., Drouot, N., et al. (2010). Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. *Neurogenetics* 11, 1–12. 10.1007/S10048-009-0196-Y.
26. Gudmundsson, S., Singer-Berk, M., Watts, N.A., Phu, W., Goodrich, J.K., Solomonson, M., Rehm, H.L., MacArthur, D.G., and O'Donnell-Luria, A. (2022). Variant interpretation using population databases: Lessons from gnomAD. *Hum Mutat* 43, 1012. 10.1002/HUMU.24309.
27. Southey, M.C., Goldgar, D.E., Winqvist, R., Pylkäs, K., Couch, F., Tischkowitz, M., Foulkes, W.D., Dennis, J., Michailidou, K., van Rensburg, E.J., et al. (2016). PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *J Med Genet* 53, 800–811. 10.1136/JMEDGENET-2016-103839.
28. Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., Byrd, P., Taylor, M., and Easton, D.F. (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. *J Natl Cancer Inst* 97, 813–822. 10.1093/JNCI/DJI141.

29. Abou Tayoun, A.N., Pesaran, T., DiStefano, M.T., Oza, A., Rehm, H.L., Biesecker, L.G., and Harrison, S.M. (2018). Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. *Hum Mutat* 39, 1517–1524. [10.1002/HUMU.23626](https://doi.org/10.1002/HUMU.23626).
30. Laake, K., Jansen, L., Hahnemann, J., Brondum-Nielsen, K., Lonngvist, T., Kaariainen, H., Sankila, R., Lahdesmaki, A., Hammarstrom, L., Yuen, J., et al. (2000). Characterization of ATM mutations in 41 Nordic families with ataxia telangiectasia. *Hum Mutat* 16, 232–246.
31. Vořechovský, I., Luo, L., Prudente, S., Chessa, L., Russo, G., Kanariou, M., James, M., Negrini, M., Webster, A.D.B., and Hammarström, L. (1996). Exon-scanning mutation analysis of the ATM gene in patients with ataxia-telangiectasia. *Eur J Hum Genet* 4, 352–355. [10.1159/000472231](https://doi.org/10.1159/000472231).
32. Teraoka, S.N., Telatar, M., Becker-Catania, S., Liang, T., Öngüt, S., Tolun, A., Chessa, L., Sanal, Ö., Bernatowska, E., Gatti, R.A., et al. (1999). Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. *Am J Hum Genet* 64, 1617–1631. [10.1086/302418](https://doi.org/10.1086/302418).
33. Landrith, T., Li, B., Cass, A.A., Conner, B.R., LaDuca, H., McKenna, D.B., Maxwell, K.N., Domchek, S., Morman, N.A., Heinlen, C., et al. (2020). Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes. *NPJ Precis Oncol* 4. [10.1038/S41698-020-0109-Y](https://doi.org/10.1038/S41698-020-0109-Y).
34. Stakyte, K., Rotheneder, M., Lammens, K., Bartho, J.D., Grädler, U., Fuchß, T., Pehl, U., Alt, A., van de Logt, E., and Hopfner, K.P. (2021). Molecular basis of human ATM kinase inhibition. *Nat Struct Mol Biol* 28, 789–798. [10.1038/S41594-021-00654-X](https://doi.org/10.1038/S41594-021-00654-X).
35. Baretic, D., Pollard, H.K., Fisher, D.I., Johnson, C.M., Santhanam, B., Truman, C.M., Kouba, T., Fersht, A.R., Phillips, C., and Williams, R.L. (2017). Structures of closed and open conformations of dimeric human ATM. *Sci Adv* 3. [10.1126/SCIADV.1700933](https://doi.org/10.1126/SCIADV.1700933).
36. Yates, L.A., Williams, R.M., Hailemariam, S., Ayala, R., Burgers, P., and Zhang, X. (2020). Cryo-EM Structure of Nucleotide-Bound Tel1ATM Unravels the Molecular Basis of Inhibition and Structural Rationale for Disease-Associated Mutations. *Structure* 28, 96-104.e3. [10.1016/J.STR.2019.10.012](https://doi.org/10.1016/J.STR.2019.10.012).
37. Xiao, J., Liu, M., Qi, Y., Chaban, Y., Gao, C., Pan, B., Tian, Y., Yu, Z., Li, J., Zhang, P., et al. (2019). Structural insights into the activation of ATM kinase. *Cell Res* 29, 683–685. [10.1038/S41422-019-0205-0](https://doi.org/10.1038/S41422-019-0205-0).
38. Lee, J.H., and Paull, T.T. (2007). Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. *Oncogene* 26, 7741–7748. [10.1038/SJ.ONC.1210872](https://doi.org/10.1038/SJ.ONC.1210872).
39. Verhagen, M.M.M., Abdo, W.F., Willemsen, M.A.A.P., Hogervorst, F.B.L., Smeets, D.F.C.M., Hiel, J.A.P., Brunt, E.R., Van Rijn, M.A., Majoor Krakauer, D., Oldenburg, R.A., et al. (2009). Clinical spectrum of ataxia-telangiectasia in adulthood. *Neurology* 73, 430–437. [10.1212/WNL.0B013E3181AF33BD](https://doi.org/10.1212/WNL.0B013E3181AF33BD).
40. Van Os, N.J.H., Chessa, L., Weemaes, C.M.R., Van Deuren, M., Fiévet, A., Van Gaalen, J., Mahlaoui, N., Roeleveld, N., Schrader, C., Schindler, D., et al. (2019). Genotype-phenotype correlations in ataxia telangiectasia patients with ATM c.3576G>A and c.8147T>C mutations. *J Med Genet* 56, 308–316. [10.1136/JMEDGENET-2018-105635](https://doi.org/10.1136/JMEDGENET-2018-105635).

41. Dörk, T., Bendix-Waltes, R., Wegner, R.D., and Stumm, M. (2004). Slow progression of ataxia-telangiectasia with double missense and in frame splice mutations. *Am J Med Genet A* 126A, 272–277. 10.1002/AJMG.A.20601.
42. Zannolli, R., Sabrina Buoni, Betti, G., Salvucci, S., Plebani, A., Soresina, A., Pietrogrande, M.C., Martino, S., Leuzzi, V., Finocchi, A., et al. (2012). A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. *Mov Disord* 27, 1312–1316. 10.1002/MDS.25126.
43. Chessa, L., Petrinelli, P., Antonelli, A., Fiorilli, M., Elli, R., Marcucci, L., Federico, A., and Gandini, E. (1992). Heterogeneity in ataxia-telangiectasia: classical phenotype associated with intermediate cellular radiosensitivity. *Am J Med Genet* 42, 741–746. 10.1002/AJMG.1320420524.
44. Magliozzi, M., Piane, M., Torrente, I., Sinibaldi, L., Rizzo, G., Savio, C., Lulli, P., De Luca, A., Dallapiccola, B., and Chessa, L. (2006). DHPLC screening of ATM gene in Italian patients affected by ataxia-telangiectasia: fourteen novel ATM mutations. *Dis Markers* 22, 257–264. 10.1155/2006/740493.
45. Gilad, S., Khosravi, R., Shkedy, D., Uziel, T., Ziv, Y., Savitsky, K., Rotman, G., Smith, S., Chessa, L., Jorgensen, T.J., et al. (1996). Predominance of null mutations in ataxia-telangiectasia. *Hum Mol Genet* 5, 433–439. 10.1093/HMG/5.4.433.
46. Mitui, M., Bernatowska, E., Pietrucha, B., Piotrowska-Jastrzebska, J., Eng, L., Nahas, S., Teraoka, S., Sholty, G., Purayidom, A., Concannon, P., et al. (2005). ATM gene founder haplotypes and associated mutations in Polish families with ataxia-telangiectasia. *Ann Hum Genet* 69, 657–664. 10.1111/J.1529-8817.2005.00199.X.
47. Stankovic, T., Kidd, A.M.J., Sutcliffe, A., McGuire, G.M., Robinson, P., Weber, P., Bedenham, T., Bradwell, A.R., Easton, D.F., Lennox, G.G., et al. (1998). ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. *Am J Hum Genet* 62, 334–345. 10.1086/301706.
48. Davis, M.Y., Keene, C.D., Swanson, P.D., Sheehy, C., and Bird, T.D. (2013). Novel mutations in ataxia telangiectasia and AOA2 associated with prolonged survival. *J Neurol Sci* 335, 134–138. 10.1016/J.JNS.2013.09.014.
49. Verhagen, M.M.M., Last, J.I., Hogervorst, F.B.L., Smeets, D.F.C.M., Roeleveld, N., Verheijen, F., Catsman-Berrevoets, C.E., Wulffraat, N.M., Cobben, J.M., Hiel, J., et al. (2012). Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. *Hum Mutat* 33, 561–571. 10.1002/HUMU.22016.
50. Buzin, C.H., Gatti, R.A., Nguyen, V.Q., Wen, C.Y., Mitui, M., Sanal, O., Chen, J.S., Nozari, G., Mengos, A., Li, X., et al. (2003). Comprehensive scanning of the ATM gene with DOVAM-S. *Hum Mutat* 21, 123–131. 10.1002/HUMU.10158.
51. Schon, K., van Os, N.J.H., Oscroft, N., Baxendale, H., Scoffings, D., Ray, J., Suri, M., Whitehouse, W.P., Mehta, P.R., Everett, N., et al. (2019). Genotype, extrapyramidal features, and severity of variant ataxia-telangiectasia. *Ann Neurol* 85, 170–180. 10.1002/ANA.25394.

52. Byrd, P.J., Srinivasan, V., Last, J.I., Smith, A., Biggs, P., Carney, E.F., Exley, A., Abson, C., Stewart, G.S., Izatt, L., et al. (2012). Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia. *Br J Cancer* *106*, 262–268. [10.1038/BJC.2011.534](https://doi.org/10.1038/BJC.2011.534).
53. Reiman, A., Srinivasan, V., Barone, G., Last, J.I., Wootton, L.L., Davies, E.G., Verhagen, M.M., Willemsen, M.A., Weemaes, C.M., Byrd, P.J., et al. (2011). Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. *Br J Cancer* *105*, 586–591. [10.1038/BJC.2011.266](https://doi.org/10.1038/BJC.2011.266).
54. Sandoval, N., Platzer, M., Rosenthal, A., Dörk, T., Bendix, R., Skawran, B., Stuhmann, M., Wegner, R.D., Sperling, K., Banin, S., et al. (1999). Characterization of ATM gene mutations in 66 ataxia telangiectasia families. *Hum Mol Genet* *8*, 69–79. [10.1093/HMG/8.1.69](https://doi.org/10.1093/HMG/8.1.69).
55. Isik, E., Onay, H., Atik, T., Canda, E., Cogulu, O., Coker, M., and Ozkinay, F. (2019). Clinical utility of a targeted next generation sequencing panel in severe and pediatric onset Mendelian diseases. *Eur J Med Genet* *62*. [10.1016/J.EJMG.2019.103725](https://doi.org/10.1016/J.EJMG.2019.103725).
56. Cavaliere, S., Funaro, A., Pappi, P., Migone, N., Gatti, R.A., and Brusco, A. (2008). Large genomic mutations within the ATM gene detected by MLPA, including a duplication of 41 kb from exon 4 to 20. *Ann Hum Genet* *72*, 10–18. [10.1111/J.1469-1809.2007.00399.X](https://doi.org/10.1111/J.1469-1809.2007.00399.X).
57. Carney, E.F., Srinivasan, V., Moss, P.A., and Taylor, A.M. (2012). Classical ataxia telangiectasia patients have a congenitally aged immune system with high expression of CD95. *J Immunol* *189*, 261–268. [10.4049/JIMMUNOL.1101909](https://doi.org/10.4049/JIMMUNOL.1101909).
58. Liu, X.L., Wang, T., Huang, X.J., Zhou, H.Y., Luan, X.H., Shen, J.Y., Chen, S. Di, and Cao, L. (2016). Novel ATM mutations with ataxia-telangiectasia. *Neurosci Lett* *611*, 112–115. [10.1016/J.NEULET.2015.11.036](https://doi.org/10.1016/J.NEULET.2015.11.036).
59. Chessa, L., Piane, M., Magliozzi, M., Torrente, I., Savio, C., Lulli, P., De Luca, A., and Dallapiccola, B. (2009). Founder effects for ATM gene mutations in Italian Ataxia Telangiectasia families. *Ann Hum Genet* *73*, 532–539. [10.1111/J.1469-1809.2009.00535.X](https://doi.org/10.1111/J.1469-1809.2009.00535.X).
60. McConville, C.M., Stankovic, T., Byrd, P.J., McGuire, G.M., Yao, Q.Y., Lennox, G.G., and Taylor, A.M.R. (1996). Mutations associated with variant phenotypes in ataxia-telangiectasia. *Am J Hum Genet* *59*, 320.
61. Toyoshima, M., Hara, T., Zhang, H., Yamamoto, T., Akaboshi, S., Nanba, E., Ohno, K., Hori, N., Sato, K., and Takeshita, K. (1998). Ataxia-telangiectasia without immunodeficiency: novel point mutations within and adjacent to the phosphatidylinositol 3-kinase-like domain - PubMed. *Am J Hum Genet*, 141–144.
62. Byrd, P.J., Srinivasan, V., Last, J.I., Smith, A., Biggs, P., Carney, E.F., Exley, A., Abson, C., Stewart, G.S., Izatt, L., et al. (2012). Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia. *Br J Cancer* *106*, 262–268. [10.1038/BJC.2011.534](https://doi.org/10.1038/BJC.2011.534).
63. Lin, J.H., Tang, X.Y., Boulling, A., Zou, W. Bin, Masson, E., Fichou, Y., Raud, L., Le Tertre, M., Deng, S.J., Berlivet, I., et al. (2019). First estimate of the scale of canonical 5' splice site GT>GC variants capable of generating wild-type transcripts. *Hum Mutat* *40*, 1856–1873. [10.1002/HUMU.23821](https://doi.org/10.1002/HUMU.23821).

64. Walker, L.C., Hoya, M. de la, Wiggins, G.A.R., Lindy, A., Vincent, L.M., Parsons, M.T., Canson, D.M., Bis-Brewer, D., Cass, A., Tchourbanov, A., et al. (2023). Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup. *Am J Hum Genet.* 10.1016/J.AJHG.2023.06.002.
65. Ioannidis, N.M., Rothstein, J.H., Pejaver, V., Middha, S., McDonnell, S.K., Baheti, S., Musolf, A., Li, Q., Holzinger, E., Karyadi, D., et al. (2016). REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet* 99, 877–885. 10.1016/J.AJHG.2016.08.016.
66. Choi, Y., and Chan, A.P. (2015). PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics* 31, 2745. 10.1093/BIOINFORMATICS/BTV195.
67. Choi, Y., Sims, G.E., Murphy, S., Miller, J.R., and Chan, A.P. (2012). Predicting the functional effect of amino acid substitutions and indels. *PLoS One* 7. 10.1371/JOURNAL.PONE.0046688.
68. Cubuk, C., Garrett, A., Choi, S., King, L., Loveday, C., Torr, B., Burghel, G.J., Durkie, M., Callaway, A., Robinson, R., et al. (2021). Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes. *Genet Med* 23, 2096–2104. 10.1038/S41436-021-01265-Z.
69. Jaganathan, K., Kyriazopoulou Panagiotopoulou, S., McRae, J.F., Darbandi, S.F., Knowles, D., Li, Y.I., Kosmicki, J.A., Arbelaez, J., Cui, W., Schwartz, G.B., et al. (2019). Predicting Splicing from Primary Sequence with Deep Learning. *Cell* 176, 535–548.e24. 10.1016/J.CELL.2018.12.015.
70. Scott, S.P., Bendix, R., Chen, P., Clark, R., Dörk, T., and Lavin, M.F. (2002). Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. *Proc Natl Acad Sci U S A* 99, 925–930. 10.1073/PNAS.012329699.
71. Barone, G., Groom, A., Reiman, A., Srinivasan, V., Byrd, P.J., and Taylor, A.M.R. (2009). Modeling ATM mutant proteins from missense changes confirms retained kinase activity. *Hum Mutat* 30, 1222–1230. 10.1002/HUMU.21034.
72. Brnich, S.E., Abou Tayoun, A.N., Couch, F.J., Cutting, G.R., Greenblatt, M.S., Heinen, C.D., Kanavy, D.M., Luo, X., McNulty, S.M., Starita, L.M., et al. (2019). Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. *Genome Med* 12. 10.1186/S13073-019-0690-2.
73. Saunders-Pullman, R., Raymond, D., Stoessl, A.J., Hobson, D., Nakamura, T., Pullman, S., Lefton, D., Okun, M.S., Uitti, R., Sachdev, R., et al. (2012). Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. *Neurology* 78, 649–657. 10.1212/WNL.0B013E3182494D51.
74. Feliubadaló, L., Moles-Fernández, A., Santamariña-Pena, M., Sánchez, A.T., López-Novo, A., Porras, L.M., Blanco, A., Capellá, G., de la Hoya, M., Molina, I.J., et al. (2021). A Collaborative Effort to Define Classification Criteria for ATM Variants in Hereditary Cancer Patients. *Clin Chem* 67, 518–533. 10.1093/CLINCHEM/HVAA250.

Declaration of Interests

MA and SN were a paid employee of Invitae. MER, TB, TP, CCY, and were paid employees of Ambry Genetics. LZ was a paid employee of Natera. SH was a paid employee of GeneDx.


FUNDING

The HBOP VCEP is supported, in part, by U24CA258058 (MBS, MC, FJC, MdlH). In addition: MH is supported by NIH grant 5U24CA258058; MdlH is supported by the Spanish Ministry of Science and Innovation, Plan Nacional de I+D+I 2013-2016, ISCIII (PI20/00110) co-funded by FEDER from Regional Development European Funds (European Union) and by NIH grant 5U24CA258058-02; ABS is supported by NHMRC Investigator Fellowship (APP177524); LCW is supported by the New Zealand Health Research Council (22/187); CT is supported by Cancer Research UK (EDDPGM-Nov22/100004); MT was supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312); WDF was supported by the Canadian Institutes of Health Research FDN 148390; MC was supported by the Bassett Center for BRCA Research; ANM is supported by Breast Cancer Research Foundation; FJC is supported by NIH grants R35CA253187 and P50CA116201 and the Breast Cancer Research Foundation

ACKNOWLEDGEMENTS

Lidia Feliubadaló, Patrick Concannon, R. Malcolm Taylor, Melissa Southey, Kelly McGoldrick, Sarah Brnich, Sarah Nielson, Huma Rana, Deborah Ritter, Steven Harrison, Sharon Plon, Heidi Rehm, Leslie Biesecker, ClinGen SVI, Hereditary Cancer Clinical domain WG executive committee

Supplementary Figure 1



Supplementary Figure 1. In-Frame Losses in the N-Solenoid Domain Cause A-T. A) The ATM gene depicted exon-by-exon as in Figure 2 (gray text on bottom is total exon numbering) with in frame exons within the N-Solenoid domain indicated by yellow text. Yellow down-facing arrows indicate a variant identified at that splice junction in a patient with A-T. Details of the observed in-frame splice defect, patient genotype and citation are described in the table.

Supplementary Table 1.

Supplementary Table 1. N-Solenoid losses for A-T Patients

Site c. (Exon)	Observed transcript (p.)	# AA lost	Ataxia-Telangiectasia Patients
c.332 (Exon 5)	r.332_496del (p.Arg111_Glu166delinsK) ¹	56	ATM c.332-1G>A CH with ATM c.2250G>A ¹
c.496 (Exon 5)	r.332_496del (p.Arg111_Glu166delinsK) ²	56	ATM c.496+5G>A CH with ATM c.7875_7876delTGinsGC ²⁻⁴
c.1607 (Exon 10)	r.1407_1607del (p.Arg469_Cys536delinsSer) ⁷	67	ATM c.1607+1G>T homozygous and CH with ATM c.3576G>A (p.K1192K) or variant not identified ⁵⁻⁸
	Intron retention also reported ⁵		
c.1898 (Exon 12)	r.1803_1898del (p.Asn602_Cys633del) ⁹	32	ATM c.1898+1G>T CH with ATM EX21_29del ⁹ ; ATM c.1898+2T>G CH with ATM c.5825C>T (p.A1942V), c.3085_6086insA, or unidentified 2nd variant ¹⁰⁻¹²
c.2250 (Exon 14)	r.2125_2250del (p.Ile709_Lys750del) (Ambry, internal data)	42	ATM c.332-1G>A CH with ATM c.2250G>A ¹
c.2376 (Exon 15)	r.2251_2376del (p.Ser751_Lys792del) (Ambry, internal data)	42	ATM c.2376+1G>A CH with ATM c.7875_7876delTGinsGC ¹³
c.2466 (Exon 16)	r.2377_2466del (p.Lys793_Leu822del) (Ambry, internal data)	30	ATM c.2466+1delG CH with ATM c.6913C>T (p.Q2305*) or unidentified 2nd variant ^{5,9,14}

c.3576 (Exon 24)	r.3403_3576del (p.Ser1135_K1192del) ^{17,18}	58	ATM c.3576G>A CH with c.3111delT, c.2413C>T (p.Arg805*), c.1369C>T (p.Arg457*), c.4842_4843insCT, c.8545C>T (p.Arg2849*); c.1607+1G>T; c.6761A>C (p.His2254Pro) ^{5,9,15,16,17} ; ATM c.3576G>A homozygous (2 patients) ^{7,13,15,18}
c.4776 (Exon 31)	r.4612_4776del165 (p.V1538_E1592del) ²⁰	55	ATM c.4776+1G>T CH with ATM c.748C>T (p.Arg250*); c.8977C>T (p.Arg2993*); or unknown variant ^{11,19,20} ; ATM c.4776+2T>C homozygote ^{5,7}
CH = Compound Heterozygous			

Supplementary Table 1 References

1. Laake, K., Jansen, L., Hahnemann, J., Brondum-Nielsen, K., Lonnqvist, T., Kaariainen, H., Sankila, R., Lahdesmaki, A., Hammarstrom, L., Yuen, J., et al. (2000). Characterization of ATM mutations in 41 Nordic families with ataxia telangiectasia. *Hum Mutat* 16, 232–246.
2. Dörk, T., Bendix-Waltes, R., Wegner, R.D., and Stumm, M. (2004). Slow progression of ataxia-telangiectasia with double missense and in frame splice mutations. *Am J Med Genet A* 126A, 272–277. 10.1002/AJMG.A.20601.
3. Van Os, N.J.H., Chessa, L., Weemaes, C.M.R., Van Deuren, M., Fiévet, A., Van Gaalen, J., Mahlaoui, N., Roeleveld, N., Schrader, C., Schindler, D., et al. (2019). Genotype-phenotype correlations in ataxia telangiectasia patients with ATM c.3576G>A and c.8147T>C mutations. *J Med Genet* 56, 308–316. 10.1136/JMEDGENET-2018-105635.
4. Verhagen, M.M.M., Abdo, W.F., Willemsen, M.A.A.P., Hogervorst, F.B.L., Smeets, D.F.C.M., Hiel, J.A.P., Brunt, E.R., Van Rijn, M.A., Majoor Krakauer, D., Oldenburg, R.A., et al. (2009). Clinical spectrum of ataxia-telangiectasia in adulthood. *Neurology* 73, 430–437. 10.1212/WNL.0B013E3181AF33BD.
5. Teraoka, S.N., Telatar, M., Becker-Catania, S., Liang, T., Önengüt, S., Tolun, A., Chessa, L., Sanal, Ö., Bernatowska, E., Gatti, R.A., et al. (1999). Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. *Am J Hum Genet* 64, 1617–1631. 10.1086/302418.
6. Magliozzi, M., Piane, M., Torrente, I., Sinibaldi, L., Rizzo, G., Savio, C., Lulli, P., De Luca, A., Dallapiccola, B., and Chessa, L. (2006). DHPLC screening of ATM gene in Italian patients affected by ataxia-telangiectasia: fourteen novel ATM mutations. *Dis Markers* 22, 257–264. 10.1155/2006/740493.
7. Gilad, S., Khosravi, R., Shkedy, D., Uziel, T., Ziv, Y., Savitsky, K., Rotman, G., Smith, S., Chessa, L., Jorgensen, T.J., et al. (1996). Predominance of null mutations in ataxia-telangiectasia. *Hum Mol Genet* 5, 433–439. 10.1093/HMG/5.4.433.
8. Telatar, M., Teraoka, S., Wang, Z., Chun, H.H., Liang, T., Castellvi-Bel, S., Udari, N., Borresen-Dale, A.L., Chessa, L., Bernatowska-Matuszkiewicz, E., et al. (1998). Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. *Am J Hum Genet* 62, 86–97. 10.1086/301673.
9. Cavalieri, S., Funaro, A., Pappi, P., Migone, N., Gatti, R.A., and Brusco, A. (2008). Large genomic mutations within the ATM gene detected by MLPA, including a duplication of 41 kb from exon 4 to 20. *Ann Hum Genet* 72, 10–18. 10.1111/J.1469-1809.2007.00399.X.
10. Davis, M.Y., Keene, C.D., Swanson, P.D., Sheehy, C., and Bird, T.D. (2013). Novel mutations in ataxia telangiectasia and AOA2 associated with prolonged survival. *J Neurol Sci* 335, 134–138. 10.1016/J.JNS.2013.09.014.

11. Mitui, M., Bernatowska, E., Pietrucha, B., Piotrowska-Jastrzebska, J., Eng, L., Nahas, S., Teraoka, S., Sholty, G., Purayidom, A., Concannon, P., et al. (2005). ATM gene founder haplotypes and associated mutations in Polish families with ataxia-telangiectasia. *Ann Hum Genet* 69, 657–664. 10.1111/J.1529-8817.2005.00199.X.
12. Stankovic, T., Kidd, A.M.J., Sutcliffe, A., McGuire, G.M., Robinson, P., Weber, P., Bedenham, T., Bradwell, A.R., Easton, D.F., Lennox, G.G., et al. (1998). ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. *Am J Hum Genet* 62, 334–345. 10.1086/301706.
13. Verhagen, M.M.M., Last, J.I., Hogervorst, F.B.L., Smeets, D.F.C.M., Roeleveld, N., Verheijen, F., Catsman-Berrevoets, C.E., Wulffraat, N.M., Cobben, J.M., Hiel, J., et al. (2012). Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. *Hum Mutat* 33, 561–571. 10.1002/HUMU.22016.
14. Zannolli, R., Sabrina Buoni, Betti, G., Salvucci, S., Plebani, A., Soresina, A., Pietrogrande, M.C., Martino, S., Leuzzi, V., Finocchi, A., et al. (2012). A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. *Mov Disord* 27, 1312–1316. 10.1002/MDS.25126.
15. Chessa, L., Piane, M., Magliozzi, M., Torrente, I., Savio, C., Lulli, P., De Luca, A., and Dallapiccola, B. (2009). Founder effects for ATM gene mutations in Italian Ataxia Telangiectasia families. *Ann Hum Genet* 73, 532–539. 10.1111/J.1469-1809.2009.00535.X.
16. Jacquemin, V., Rieunier, G., Jacob, S., Bellanger, D., D'Enghien, C.D., Laugé, A., Stoppa-Lyonnet, D., and Stern, M.H. (2012). Underexpression and abnormal localization of ATM products in ataxia telangiectasia patients bearing ATM missense mutations. *Eur J Hum Genet* 20, 305–312. 10.1038/EJHG.2011.196.
17. Sandoval, N., Platzer, M., Rosenthal, A., Dörk, T., Bendix, R., Skawran, B., Stuhmann, M., Wegner, R.D., Sperling, K., Banin, S., et al. (1999). Characterization of ATM gene mutations in 66 ataxia telangiectasia families. *Hum Mol Genet* 8, 69–79. 10.1093/HMG/8.1.69.
18. Demuth, I., Dutrannoy, V., Marques, W., Neitzel, H., Schindler, D., Dimova, P.S., Chrzanowska, K.H., Bojinova, V., Gregorek, H., Graul-Neumann, L.M., et al. (2011). New mutations in the ATM gene and clinical data of 25 AT patients. *Neurogenetics* 12, 273–282. 10.1007/S10048-011-0299-0.
19. Broccoletti, T., Del Giudice, E., Cirillo, E., Vigliano, I., Giardino, G., Ginocchio, V.M., Bruscoli, S., Riccardi, C., and Pignata, C. (2011). Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. *Eur J Neurol* 18, 564–570. 10.1111/J.1468-1331.2010.03203.X.
20. Fiévet, A., Bellanger, D., Rieunier, G., Dubois d'Enghien, C., Sophie, J., Calvas, P., Carriere, J.P., Anheim, M., Castrioto, A., Flabeau, O., et al. (2019). Functional classification of ATM variants in ataxia-telangiectasia patients. *Hum Mutat* 40, 1713–1730. 10.1002/HUMU.23778.

Supplementary Table 2. SpATM-WG vs HBOP Classification Criteria Comparison.

	Spanish ATM Working Group (SpATM-WG)	ClinGen HBOP VCEP	Difference	Rationale	
Population	BA1-Population Frequency Stand Alone	>.5%	>.5% per filtering allele frequency	HBOP more conservative	
	BS1-Population Frequency Strong	>.05%	>.05% per filtering allele frequency	HBOP more conservative	
	PM2-Rarity	<.001% in total gnomAD or <.002% in sub-population gnomAD if N≥2	<.001% in all sub-populations Singletons receive PM2_Supporting regardless of allele frequency	HBOP more conservative	
Computational/Predictive	BP1-Missense in a LoF Gene	N/A	N/A	No difference	
	BP3-in frame indel in a repeat region	N/A	N/A	No difference	
	BP4-in silico benign	VEST4 & REVEL <.5 (domain restricted) SPICE 2.1: <0.240 (donor) <0.282 (acceptor)	REVEL <.249 SpliceAI ≤.1	HBOP less conservative	HBOP requires only one metapredictor and does not restrict its use by domain or position.
	PP3-in silico deleterious	VEST4 & REVEL >.5 (domain restricted) SPICE 2.1: ≥0.240 (donor) ≥0.789 (acceptor)	REVEL >.733 SpliceAI ≥.2	HBOP less conservative	HBOP requires only one metapredictor and does not restrict its use by domain or position.
	BP5-different-gene co-occurrences	N/A	N/A	No difference	
	BP7-synonymous/deep intronic	Unconserved synonymous	Synonymous and deep-intronic	HBOP ignores conservation and includes deep-intronic per SVI guidelines	
	PP2-missense constraint	N/A	N/A	No difference	
	PM4-in frame indel and stop-loss	Applies: codon and domain-specific	Use for stop-loss only	HBOP more conservative	HBOP does not allow PM4 for in frame events due to inability to accurately predict which are pathogenic and which are neutral
	PM5-missense hotspot	Applies: in silico informed restrictions	Does not apply as hotspot. Co-opted code (as supporting) for truncations upstream of p.Arg3047	HBOP more conservative HBOP less conservative	HBOP does not allow PM5 as a hotspot due to inability to accurately predict which are pathogenic and which are neutral. SpATM-WG does not use PM5_Supporting as a co-opted code
	PM1-structural domain hotspot	Applies: codon and domain-specific	N/A	HBOP more conservative	HBOP did not conduct a similar analysis as SpATM-WG because frequency is not a sole predictor of pathogenicity
	PS1-same AA change as LP/P	Applies for protein. Also used (as supporting) for RNA hotspot	Applies for protein. Also used for RNA hotspot with restrictions per SVI guidelines	HBOP more current	SVI guidelines for RNA were not published at the time of SpATM-WG's publication
	Phenotype Data	BS2-Healthy Adult	Used for biallelic healthy patients with restrictions	N/A	Code difference
PVS1-LoF		Reference SVI's Tayoun et al	Detailed Decision Tree Provided	HBOP more current	
PP4-phenotype highly consistent		N/A	N/A	No difference	
PS4-case control/proband counting		Applies at variable weight: proband counting of A-T families with restrictions.	Case Control Only; no proband counting	Code difference	
Functional	BS3-functional benign	Applies to RNA and Protein studies. Protein studies include patient- or cell line studies ascertaining ATM auto- and trans-phosphorylation and sensitivity to DNA damaging agents	Applies to protein studies: Protein studies include ATM-null cell lines ascertaining ATM-specific phosphorylation and/or radiosensitivity. Max weight BS3_Supporting each.	HBOP more conservative	
	PS3-functional pathogenic	Applies to RNA and Protein studies. Protein studies include patient- or cell line studies ascertaining ATM auto- and trans-phosphorylation and sensitivity to DNA damaging agents. Max weight PS3 as strong	Applies to protein studies: Protein studies include ATM-null cell lines ascertaining ATM-specific phosphorylation and radiosensitivity. Max weight PS3_Moderate for both or PS3_Supporting for ATM-specific event only. No weight for radiosensitivity-only.	HBOP more conservative	
	BP7(RNA)-assay with no aberrant splicing	Coded as BS3	Applies per SVI guidelines	HBOP more current	
	PVS1(RNA)-assay with aberrant splicing	Coded as PS3	Applies per SVI guidelines	HBOP more current	

Segregation	BS4-non segregation	Applies to A-T families	N/A	Different codes	HBOP would apply unaffected biallelic patients (even if siblings of an A-T patient) as BP2, instead
	PP1-segregation with disease	Applies to A-T families	N/A	HBOP more conservative	Segregation within A-T families is extremely rare in the literature and cannot be used to inform the appropriate weighting of such occurrences at this time
de novo	PM6-presumed <i>de novo</i>	Applies to A-T families	N/A	HBOP more conservative	De novo occurrences in the heterozygous state are not informative. De novo occurrences in the biallelic state would be challenging to determine phase without long-read technologies due to the size of ATM
	PS2-confirmed <i>de novo</i>	Applies to A-T families	N/A		
Allelic	BP2-biallelic unaffected	Applies. Unrestricted	Applies with restrictions	HBOP more conservative	Additional precautions are applied around the age of the proband, the phase/zygosity, the diagnostic setting and the variant population frequency
	PM3-biallelic affected	Applies per ClinGen SVI Recommendations PM3 Version 1.0 with restrictions	Applies at double the weight from SVI Recommendations for PM3 Version 1.0. Restrictions for phenotype specificity, phase/zygosity, variant classifications	HBOP is less conservative	There is a 1:1 relationship between the genotype and phenotype from A-T patients. A-T clinical criteria are detailed in HBOP rules